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Cover:  CYP2D6 Tamoxifen Pharmacogenetics in Breast Cancer. 
Tamoxifen is a standard of care for patients whose tumors stain positive for 
the estrogen receptor (ER) by immunohistochemstry (lower right panel). The 
background figure shows an LC/MS/MS analytical profile of steady-state 
plasma levels of tamoxifen and its metabolites in a patient treated with a 
daily dose of 20 mg tamoxifen. Levels of (Z)-Endoxifen, one of the active 
metabolites (center) follow a CYP2D6 gene dose effect (upper left panel, > 
230 patients). Patients with no or low function alleles (PM) have lowest, 
patients with impaired enzyme activity (IM) have intermediate, and patients 
with two and more full function alleles (EM and UM, respectively) have 
highest Endoxifen levels (expressed as metabolic ratio of the precursor 
metabolite). Image provided by Thomas Mürdter and Hiltrud Brauch, Dr. 
Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, and 
University Tübingen, Germany. 
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PROGRAM 
 
 
WEDNESDAY, November 17—7:30 PM 
 
 
SESSION 1 OPENING SESSION 
 
 
En route to the era of genomic medicine 
Eric D. Green. 
Presenter affiliation: NHGRI, National Institutes of Health, Bethesda, 
Maryland. 
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Pharmacogenetics / genomics—Past, present and future 
Michel Eichelbaum. 
Presenter affiliation: Dr. Margarete Fischer-Bosch-Institute of Clinical 
Pharmacology, Stuttgart, Germany. 
 
 
 
2 
 
 
THURSDAY, November 18—9:00 AM 
 
 
SESSION 2 TRANSLATIONAL BIOINFORMATICS 
 
Chairperson: E. Schadt, Pacific Biosciences, Menlo Park, California 
 
  
An integrative genomics strategy to elucidating the complexity of 
drug response 
Eric E. Schadt. 
Presenter affiliation: Pacific Biosciences, Menlo Park, California. 
 
 
 
3 
  
Development of multi-SNP predictive models and characterization 
of performance metrics 
Scott L. Marshall, Jared R. Kohler, Laura B. Gillis, Christina M. 
Bromley. 
Presenter affiliation: BioStat Solutions, Inc., Mt. Airy, Maryland. 
 
 
 
 
4 
  
Systems (pathway) biology in pharmacogenomics research—A 
highly scalable Bayesian network modeling approach 
Andrei S. Rodin, Grigoriy Gogoshin, Stephen T. Turner, Julie A. 
Johnson, Arlene Chapman, Eric Boerwinkle. 
Presenter affiliation: University of Texas - Houston, Houston, Texas. 
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 vi 
Systems characterization of drug combination therapies in a 
mouse model of metabolic syndrome 
Marijana Radonjic, Marjan van Erk, Robert Kleemann, Teake Kooistra, 
Lars Verschuren, Peter Y. Wielinga, Ben van Ommen. 
Presenter affiliation: TNO Biosciences, Zeist, Netherlands. 
 
 
 
 
6 
  
Genetic variation in the TGF-β signaling pathway is associated 
with response to platinum-based chemotherapy and overall 
survival in ovarian cancer patients 
Michelle A.T. Hildebrandt, Xia Pu, Larissa Meyer, Carol Etzel, Jie Lin, 
Dong Liang, Karen Lu, Xifeng Wu. 
Presenter affiliation: University of Texas MD Anderson Cancer Center, 
Houston, Texas. 
 
 
 
 
 
 
7 
  
Identifying quantitative trait genes for in vitro drug toxicity using 
high-content screening 
Oscar Suzuki, Natasha Butz, Brian Steffy, Bethany Parks, O. Joseph 
Trask, David Scoville, Amber Frick, Daniel Crona, Russell Thomas, 
Tim Wiltshire. 
Presenter affiliation: UNC Eshelman School of Pharmacy, Chapel Hill, 
North Carolina. 
 
 
 
 
 
 
8 
  
Variation in sex steroid methyl transferases predicts efficacy to 
androgen deprivation therapy (ADT) in prostate cancer 
Manish Kohli, Douglas Mahoney, High Chai, David Hillman, James 
Cerhan. 
Presenter affiliation: Mayo Clinic, Rochester, Minnesota. 
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THURSDAY, November 18—2:00 PM 
 
 
SESSION 3 POSTER SESSION I 
 
  
GENDEP—Recent pharmacogenetic and pharmacogenomic 
output 
K.J. Aitchison, R. Keers, R. Uher, N. Perroud, R. Smith, K. Malki, J. 
Paya-Cano, M. Rietschel, O. Mors, N. Henigsberg, W. Maier, J. 
Hauser, D. Kozel, D. Souery, L. Schalkwyk, C. Lewis, I.W. Craig, P. 
McGuffin. 
Presenter affiliation: King's College London, London, United Kingdom. 
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 vii 
Identification of compounds active against mitochondrial disease 
using a novel yeast-based assay 
Elodie Couplan, Raeka S. Aiyar, Roza Kucharczyk, Nahia Ezcurdia, 
Julien Gagneur, Robert P. St. Onge, Benedicte Salin, Marie Le Cann, 
Lars M. Steinmetz, Jean-Paul di Rago, Marc Blondel. 
Presenter affiliation: European Molecular Biology Laboratory (EMBL), 
Heidelberg, Germany. 
 
 
 
 
 
 
11 
  
An association between carbamazepine-induced maculopapular 
exanthema and the HLA-C region in Caucasians 
Ana Alfirevic, Stephane Bourgeois, Andrea Jorgensen, Graeme Sills, 
Tony Marson, Michael Johnson, B Kevin Park, Munir Pirmohamed. 
Presenter affiliation: University of Liverpool, Liverpool, United 
Kingdom. 
 
 
 
 
 
12 
  
Differential effect of the rs4149056 variant in SLCO1B1 on 
myopathy associated with simvastatin and atorvastatin 
Liam R. Brunham, Peter Lansberg, Colin J. Ross, Henk Visscher, John 
K. Kastelein, Michael R. Hayden. 
Presenter affiliation:  University of British Columbia, Vancouver, 
Canada. 
 
 
 
 
 
13 
  
Analysis of cytochrome P450 2B6 haplotypes and associations 
with efavirenz plasma concentrations in a Chilean HIV cohort 
Daniel F. Carr, Charles J. La Porte, Munir Pirmohamed, Andrew Owen, 
Cortes P. Claudia. 
Presenter affiliation: University of Liverpool, Liverpool, United 
Kingdom. 
 
 
 
 
 
14 
  
The influence of multidrug and toxin extrusion 1 (MATE1) 
transporter genotypes on the pharmacokinetics of metfomin 
Sung Kweon Cho, Min Goo Lee, Kyungsoo Park, Jae-Yong Chung. 
Presenter affiliation: Yonsei University College of Medicine, Seoul, 
South Korea. 
 
 
 
 
15 
  
The sequencing era—Are pharmacogenetic profiles becoming a 
reality? 
Britt I. Drögemöller, Galen E. Wright, Dana J. Niehaus, Robin Emsley, 
Louise Warnich. 
Presenter affiliation: Stellenbosch University, Stellenbosch, South 
Africa. 
 
 
 
 
 
16 
  
 viii 
Ethnically diverse induced pluripotent stem cells for 
pharmacogenomics 
Eyitayo S. Fakunle, Sara Abdelrahman, Victoria Glenn, Daniel Mulvihill, 
Candace Lynch, Gulsah Altun, Thomas Touboul, Ronald Simon, 
Louise Laurent, Jeanne Loring. 
Presenter affiliation: The Scripps Research Institute, La Jolla, 
California. 
 
 
 
 
 
 
17 
  
Towards Individualization of prostate cancer treatment—
Characterization of a motility-related biomarker 
Albert G. Frauman, Michael W. Parker, Elizabeth D. Williams, Sujitra 
Detchokul. 
Presenter affiliation: University of Melbourne, Heidelberg, Australia. 
 
 
 
 
18 
  
Genetic findings of P2Y12 single-nucleotide polymorphisms and 
their influences on the variation in ADP-induced platelet 
aggregation 
Jong-Lyul Ghim, Su-Jun Lee, Eun-Ji Jung, Ji-Yeob Choi, Jae-Gook 
Shin. 
Presenter affiliation: Inje University Busan Paik Hospital, Busan, South 
Korea. 
 
 
 
 
 
 
19 
  
Internal and external evaluation of a pharmacometric model for 
warfarin using prediction corrected visual predictive check (PC-
VPC) 
Anna-Karin Hamberg, Mia Wadelius, Munir Pirmohamed, Niclas 
Jonsson. 
Presenter affiliation: Clin Pharmacology, Uppsala, Sweden. 
 
 
 
 
 
20 
  
Polymorphisms of sensibility genes and the risk of relapse or 
survival to childhood acute lymphoblastic leukemia in Korea 
Sujee Jeon, Sohee Han, Kyoung-Mu Lee, Sue K. Park, Hyo Seop Ahn, 
Daehee Kang. 
Presenter affiliation: Seoul National University College of Medicine, 
Seoul, South Korea. 
 
 
 
 
 
21 
  
Brain-derived neurotrophic factor gene polymorphisms and 
escitalopram responses in patients with major depression 
Yoo-Jung Jeong, Hun Soo Chang, Hwa-Young Lee, Byung-Joo Ham, 
Min-Soo Lee. 
Presenter affiliation: Korea University Hospital Depression Center, 
Seoul, South Korea. 
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 ix 
Development and validation of real-time PCR-based TPMT 
genotyping method for dose adjustment of thiopurine 
compounds 
Misuk Ji, Hye Won Lee, Keumrock Hwang, Sollip Kim, Seong-Youl 
Kim, Sang-Jin Byun, Woochang Lee, Sail Chun, Won-Ki Min. 
Presenter affiliation: Asan Medical Center, Seoul, South Korea. 
 
 
 
 
 
23 
  
Clinical characteristics and HLA analysis of acute generalized 
exanthematous pustulosis 
Hye-Ryun Kang, Jae-Woo Jung, Sang-Heon Kim, Heung-Woo Park, 
Young-Ku Jee, Kyung-Up Min. 
Presenter affiliation: Seoul National University Hospital, Seoul, South 
Korea. 
 
 
 
 
 
24 
  
Identification of a novel variant of CYP2C8, CYP2C8*11, in Asian 
populations and its effect on the rosiglitazone disposition in vivo 
Mi-Yeon Kang, Chang-woo Yeo, Sang Seop Lee, Su-Jun Lee, Hye-
Eun Jung, Jung-Soon Park, Jae-Gook Shin. 
Presenter affiliation: Inje University College of Medicine , Busan, South 
Korea. 
 
 
 
 
 
25 
  
Association of genetic variation in tamoxifen-metabolizing 
enzymes and plasma concentration of tamoxifen metabolties 
Suk Ran Kim, Se-Kyung Lee, Jeong Eon Lee, Seok-Jin Nam, Jung-
Hyun Yang, Jong-Won Kim, Soo-Youn Lee. 
Presenter affiliation: Samsung Medical Center, Sungkyunkwan 
University School of Medicine, Seoul, South Korea. 
 
 
 
 
 
26 
  
Automatic interpretation program can facilitate warfarin 
genotyping method, making faster & easier to apply in clinical 
laboratory 
Sollip Kim, Hye Won Lee, Mi-Suk Ji, Hee-Jung Chung, Woochang Lee, 
Eun Ju Cho, Dong-Sik Kim, Hae-Joon Park, Sail Chun, Won-Ki Min. 
Presenter affiliation: University of Ulsan College of Medicine and Asan 
Medical Center, Seoul, South Korea. 
 
 
 
 
 
 
27 
  
Association between MDR1 and side effects of methylphenidate 
in Korean ADHD patients 
So Won Kim, Sung Hee Lee, Ki Hwan Yook, Hyun Ju Hong, Min Goo 
Lee. 
Presenter affiliation: Yonsei University College of Medicine, Seoul, 
South Korea. 
 
 
 
 
 
28 
  
 x 
Pathway-targeted pharmacogenomics of CYP1A2 in human liver 
Kathrin Klein, Stefan Winter, Miia Turpeinen, Matthias Schwab, Ulrich 
M. Zanger. 
Presenter affiliation: Dr. Margarete Fischer-Bosch Institute of Clinical 
Pharmacology, Stuttgart, Germany. 
 
 
 
 
29 
  
Generating tetracycline inducible MRP2 cell-lines 
Rudolph Arlanov, Andrew Porter, Rachel Brough, Dennis Strand, Ute 
Gödtel-Armbrust, Matthias Schwab, Leszek Wojnowski, Thomas Lang. 
Presenter affiliation: Dr. Margarete Fischer-Bosch-Institute, Stuttgart, 
Germany. 
 
 
 
 
30 
  
A CYP2C9 haplotype exhibited a possible association with 
increased warfarin sensitivity in mechanical heart valve 
replacement patients 
Su-Jun Lee, Bo-Min Park, Yin Jin Jang, Eun-Young Cha, Ho-Sook 
Kim, Sang Seop Lee, Jae-Gook Shin. 
Presenter affiliation: Inje University College of Medicine, Busan, South 
Korea. 
 
 
 
 
 
 
31 
  
Respiratory depression following therapeutic administration of 
opioids in the operating room—An opioid pathway 
pharmacogenetic analysis 
Parvaz Madadi, Johanna Sistonen, Rebecca Gladdy, Gregory 
Silverman, Jose C. Carvalho, Colin J. Ross, Bruce C. Carleton, 
Michael R. Hayden, Gideon Koren. 
Presenter affiliation: Hospital for Sick Children, Toronto, Canada. 
 
 
 
 
 
 
32 
  
Adiponectin and PPAR-γ gene variability and risk of coronary 
heart disease in North Indian population-A case-control study 
Nishi Maithil, R.C. Sobti, Yashpaul Sharma, K.K. Talwar. 
Presenter affiliation: Panjab University, Chandigarh, India. 
 
 
 
33 
  
Perioperative pharmacogenomics—A new frontier for 
personalized medicine 
Peter Nagele, Steven B. Liggett, Guillome Pare. 
Presenter affiliation: Washington University School of Medicine, St. 
Louis, Missouri. 
 
 
 
 
34 
  
Aggregate effects of genetic variants within pathways on 
flucloxacillin and co-amoxiclav induced liver injury. 
Paola Nicoletti, Yhufeng Shen, Paolo Guarnieri, Mukesh Bansal, 
Celene Lefebvre, Itsik Pe’er, Aris Floratos, Andrea Califano. 
Presenter affiliation: Columbia University, New York, New York. 
 
 
 
 
35 
  
 xi 
Deep sequencing APOE exposes inadequacies of genetic testing 
Alexandra J. Obregon-Tito, Raul Y. Tito, Cecil M. Lewis. 
Presenter affiliation: University of Oklahoma, Norman, Oklahoma. 
 
 
36 
  
Improved asthma control with montelukast relative to salmeterol 
In ADRB2 Arg-16 homozygous children with asthma 
Kaninika Basu, Helen P. Donald, Brian J. Lipworth, Roger Tavendale, 
Donald Macgregor, Simon A. Ogston, Somnath Mukhopadhyay, Colin 
N. Palmer. 
Presenter affiliation: University of Dundee, Dundee, United Kingdom. 
 
 
 
 
 
37 
  
Genetic ploymorphism is related to dermatologic adverse drug 
reactions of antiepileptic agent. 
Joonhee Park, Sowon Kim, Mingoo Lee. 
Presenter affiliation: Yonsei University College of Medicine, Seoul, 
South Korea; Brain Korea 21 Project for Medical Science, Seoul, 
South Korea. 
 
 
 
 
 
38 
  
Methylation detection in a MCF-7 cell line using ultra high-
throughput bisulfite-sequencing with the SOLiDTM system 
Minita Jalan Shah, Vrunda Sheth, Stephen F. McLaughlin, Yutao Fu, 
Zheng Zhang, Christina Chung, Melissa A. Barker, Victoria L. Boyd, 
Gavin Meredith, Aaron Kitzmiller, Miroslav Dudas, Daniel Krissinger, 
Heather E. Peckham. 
Presenter affiliation: Life Technologies, Beverly, Massachusetts. 
 
 
 
 
 
 
39 
  
Opioid pathway pharmacogenetic analysis of neonatal opioid 
toxicity following maternal use of codeine during breastfeeding 
Johanna Sistonen, Parvaz Madadi, Colin J. Ross, Jong W. Lee, 
Mojgan Yazdanpanah, Bruce C. Carleton, Gideon Koren, Michael R. 
Hayden. 
Presenter affiliation: University of British Columbia, Vancouver, 
Canada. 
 
 
 
 
 
 
40 
  
Analysis of genotype-based warfarin dosing approaches and their 
outliers 
Carleta B. Maurice, Gary Stack. 
Presenter affiliation: VA Connecticut Healthcare System, West Haven, 
Connecticut; Yale University School of Medicine, New Haven, 
Connecticut. 
 
 
 
 
 
41 
  
 xii 
Genetic variation of membrane-bound catechol-O-
methyltransferase and susceptibility to schizophrenia and 
antipsychotic induced abnormal involuntary movements in an 
African population 
Galen E. Wright, Britt I. Drögemöller, Lize van der Merwe, Liezl Koen, 
Craig J. Kinnear, Dana J. Niehaus, Louise Warnich. 
Presenter affiliation: Stellenbosch University, Stellenbosch, South 
Africa. 
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THURSDAY, November 18—4:30 PM 
 
Wine and Cheese Party 
 
 
THURSDAY, November 18—7:30 PM 
 
 
SESSION 4 NEXT GENERATION SEQUENCING APPROACHES IN 
PHARMACOGENOMICS 
 
Chairperson: D. Nickerson, University of Washington, Seattle 
 
 
Debbie Nickerson 
Presenter affiliation: University of Washington, Seattle. 
 
  
Novel VKORC1 mutations identified in warfarin resistant patients 
Eunice J. Zhang, Ana Alfirevic, Dan Carr, Kimberley Spencer, Roger 
Mountford, Munir Pirmohamed. 
Presenter affiliation: The Wolfson Centre for Personalised Medicine, 
University of Liverpool, Liverpool, United Kingdom. 
 
 
 
 
43 
  
The genetic control of drug responses 
David B. Goldstein. 
Presenter affiliation: Duke University, Durham, North Carolina. 
 
 
44 
  
A four step genomic approach to identify predisposition to 
carbamazepine-induced hypersensitivity syndrome in Caucasian 
patients 
Ana Alfirevic, Stephane Bourgeois, Graeme Sills, Tony Marson, B 
Kevin Park, Panos Deloukas, Munir Pirmohamed. 
Presenter affiliation: University of Liverpool, Liverpool, United 
Kingdom. 
 
 
 
 
 
 
45 
  
 xiii 
Genetic risk profile predicting anthracycline-induced 
cardiotoxicity in children 
Henk Visscher, Colin J. Ross, Rod Rassekh, Amina Barhdadi, Marie-
Pierre Dubé, Hesham al-Saloos, George S. Sandor, Andrew M. Brown, 
Paul C. Rogers, Michael S. Phillips, Michael J. Rieder, Bruce C. 
Carleton, Michael R. Hayden. 
Presenter affiliation: University of British Columbia, Vancouver, 
Canada. 
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FRIDAY, November 19—9:00 AM 
 
 
SESSION 5 GENOME-WIDE ANALYSES AND CNVs 
 
Chairperson: P. Donnelly, Wellcome Trust Centre for Human Genetics,  
  Oxford, United Kingdom 
 
  
CNVs in association studies 
Peter J. Donnelly. 
Presenter affiliation: Wellcome Trust Centre for Human Genetics, 
Oxford, United Kingdom. 
 
 
 
47 
  
Prognostic impact of inherited genetic variations in SRD5A and 
androgen inactivating UGT2B genes in prostate cancer after 
prostatectomy 
Étienne Audet-Walsh, Judith Bellemare, Geneviève Nadeau, Louis 
Lacombe, Yves Fradet, Pierre Douville, Hugo Girard, Chantal 
Guillemette, Éric Lévesque. 
Presenter affiliation: Centre Hospitalier Universitaire de Québec 
(CHUQ) Research Center and Laval University, Québec, Canada. 
 
 
 
 
 
 
 
48 
  
Inherited genetic variation in FZD3 , EPHA5 and FGD4 and 
Paclitaxel (P) induced peripheral neuropathy (PN)—Results from 
a genome-wide association study (GWAS) in CALGB 40101 
Michael Baldwin, Kouros Owzar, Chen Jiang, Dee Watson, Joel 
Mefford, John S. Witte, Eric Jorgenson, Hitoshi Zembutsu, Michiaki 
Kubo, Howard L. McLeod, Clifford A. Hudis, Eric P. Winer, Yusuke 
Nakamura, Larry N. Shulman, Mark J. Ratain, Deanna L. Kroetz. 
Presenter affiliation: UCSF, San Francisco, California. 
 
 
 
 
 
 
 
49 
  
 xiv 
Genome-wide scan identifies genetic predictors of survival in 
non-small cell lung cancer patients treated with platinum-based 
chemotherapy 
Xifeng Wu, Yuanging Ye, Rafael Rosell, Christopher I. Amos, David J. 
Stewart, Michelle A.T. Hildebrandt, Jack Roth, Jian Gu, Sharma C. 
Buch, Tomoko Nukui, Charles Lu, Scott M. Lippman, Waun Ki Hong, 
Margaret R. Spitz, Marjorie Romkies, Ping Yang. 
Presenter affiliation: University of Texas MD Anderson Cancer Center, 
Houston, Texas. 
 
 
 
 
 
 
 
 
50 
  
Pharmacogenomics of tamoxifen and raloxifene in breast cancer 
prevention—GWAS and functional genomic link of a SNP signal 
to BRCA1 and BRCA2 
Richard M. Weinshilboum, Mohan Liu, James N. Ingle. 
Presenter affiliation: Mayo Clinic-PGRN-NSABP-RIKEN Coalition, 
Rochester, Minnesota. 
 
 
 
 
 
51 
  
Association of variants in the Selectin E precursor (SELE) with 
adverse outcomes in the International Verapamil SR-Trandolapril 
Study GENEtic Substudy (INVEST-GENES) 
Caitrin W. McDonough, Yan Gong, Taimour Y. Langaee, Rhonda M. 
Cooper-DeHoff, Carl J. Pepine, Julie A. Johnson. 
Presenter affiliation: University of Florida, Gainesville, Florida. 
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FRIDAY, November 19—2:00 PM 
 
 
SESSION 6 GENETIC CONTROL OF EXPRESSION 
 
Chairperson: S. Brenner, University of California, Berkeley 
 
  
CAGI—The Critical Assessment of Genome Interpretation, a 
community experiment to evaluate phenotype prediction 
Steven E. Brenner, John Moult. 
Presenter affiliation: University of California, Berkeley, Berkeley, 
California. 
 
 
 
 
53 
  
Utilizing a novel ADME genotyping panel to identify drug 
metabolism phenotype/genotype correlations in human liver 
samples 
Andrew M. Brown, Yannick Renaud, Colin Ross, Mark Hansen, Kathrin 
Klein, Ulrich M. Zanger, Jean-Claude Tardif, Michael S. Phillips. 
Presenter affiliation: Beauleiu-Saucier Universerité de Montréal 
Pharmacogenomics Centre, Montreal, Canada. 
 
 
 
 
 
 
54 
 xv 
Heritability of chemotherapeutic-induced apoptosis 
Yujia Wen, Heather Wheeler, Lidija Gorsic, M.Eileen Dolan. 
Presenter affiliation: University of Chicago, Chicago, Illinois. 
 
 
55 
  
Eukaryotic transcriptomes—Complex, multifunctional, 
compartmentalized and elegant 
Thomas Gingeras. 
Presenter affiliation: Cold Spring Harbor Laboratory, Cold Spring 
Harbor, New York. 
 
 
 
 
56 
  
Polymorphisms of the asparaginase pathway and childhood 
acute lymphoblastic leukemia outcome 
Julie Rousseau, Cyrielle Beaubois, Vincent Gagné, Caroline 
Laverdière, Maja Krajinovic. 
Presenter affiliation: CHU Sainte Justine, University of Montréal, 
Canada. 
 
 
 
 
 
57 
  
The dihydropyrimidine dehydrogenase gene as a major predictor 
of severe 5-fluorouracil toxicity—A classic reborn? 
Carlo R. Largiader, Ursula Amstutz, Tanja K. Froehlich, Simone 
Farese, Stefan Aebi, Markus Jörger, André B P. van Kuilenburg. 
Presenter affiliation: University Hospital Bern, Switzerland. 
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FRIDAY, November 19—7:30 PM 
 
 
SESSION 7 POSTER SESSION II 
 
See Poster Session I for list of posters. 
 
 
 
SATURDAY, November 20—9:00 AM 
 
 
SESSION 8 EPIGENETICS AND FUNCTIONAL GENOMICS 
 
Chairperson: M. Esteller, Bellvitge Biomedical Research Institute,  
  Barcelona, Spain 
 
  
Cancer pharmacoepigenetics—Genes and drugs 
Manel Esteller. 
Presenter affiliation: Bellvitge Biomedical Research Institute (IDIBELL), 
L'Hospitalet (Barcelona), Spain. 
 
 
 
59 
 xvi 
Aromatase inhibitor pharmacogenomics—Functional genomics of 
TCL1A GWAS signal for musculoskeletal adverse events 
Mohan Liu, James Ingle, Richard Weinshilboum. 
Presenter affiliation: Mayo Clinic PGRN-MA.27-RIKEN Coalition, 
Rochester, Minnesota. 
 
 
 
 
60 
  
Correlation of active tamoxifen metabolite levels with genotypes 
of drug metabolizing enzymes in patients with early breast cancer 
Thomas E. Mürdter, Werner Schroth, Liza Bacchus, Wolfgang Simon, 
Michel Eichelbaum, Matthias Schwab, Hiltrud Brauch. 
Presenter affiliation: Dr. Margarete Fischer-Bosch Institute, Stuttgart, 
Germany. 
 
 
 
 
 
61 
  
Exploring the relationships between genetic variants within the 
UGT1A locus, cellular detoxification and risk of bladder cancer 
Wei Tang, Yi-Ping Fu, Luyang Liu, Natalia Orduz, Alpana Kaushiva, 
Adam Mumy, Patricia Porter-Gill, Timothy Myers, Montserrat Garcia-
Closas, Nuria Malats, Stephen Chanock, Francisco X. Real, Manolis 
Kogevinas, Nathaniel Rothman, Debra Silverman, Ludmila Prokunina-
Olsson. 
Presenter affiliation: NCI, National Institutes of Health, Bethesda, 
Maryland. 
 
 
 
 
 
 
 
 
62 
  
Functional genome-wide association studies of 
chemotherapeutic response in African populations 
Heather E. Wheeler, Amy L. Stark, Eric R. Gamazon, Lidija K. Gorsic, 
Nancy J. Cox, M Eileen Dolan. 
Presenter affiliation: University of Chicago, Chicago, Illinois. 
 
 
 
 
63 
  
Radiation pharmacogenomics—Novel biomarker identification 
and functional genomics 
Liewei Wang, Nifang Niu, Yuxin Qin, Brooke L. Fridley, Junmei Hou, 
Krishna R. Kalari, Minjia Zhu, Tse-Yu Wu, Gregory D. Jenkins, 
Anthony Batzler. 
Presenter affiliation: Mayo Clinic, Rochester, Minnesota. 
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 xvii 
SATURDAY, November 20—2:00 PM 
 
 
SESSION 9 ELSI, PHARMACOECONOMIC ISSUES AND 
POPULATION-BASED PHARMACOGENETICS 
 
Chairperson: D. Veenstra, University of Washington, Seattle 
 
  
Cost-effectiveness of pharmacogenomics—Challenges and 
opportunities in an era of decreasing test cost 
David L. Veenstra. 
Presenter affiliation: University of Washington, Seattle, Washington. 
 
 
 
65 
  
Return of individual genomic research results—Perspectives of 
IRBs 
Lynn G. Dressler, Roselle Ponsaran, Sondra Smolek, Janell Markey, 
Susan B. Trinidad, Helene Starks, Nancy Gerson, Sue Lewis, Nancy 
Press, Georgia Wiesner. 
Presenter affiliation: University of North Carolina, Chapel Hill, North 
Carolina. 
 
 
 
 
 
 
66 
  
PharmGKB—From knowledge acquisition to clinical applications 
Michelle Whirl-Carrillo, Li Gong, Mei Gong, Joan Hebert, Feng Liu, 
Katrin Sangkuhl, Rebecca Tang, Caroline Thom, TC Truong, Ryan 
Whaley, Mark Woon, Tina Zhou, Russ B. Altman, Teri E. Klein. 
Presenter affiliation: Stanford School of Medicine, Palo Alto, California. 
 
 
 
 
67 
  
Influence of genetic variants of OATP1B1 on statin drug 
efficacy—Results from a population based survey 
Henriette E. Meyer zu Schwabedissen, Martin Albers, Christian 
Rimmbach, Dieter Rosskopf, Matthias Nauk, Henri Wallaschowski, 
Werner Siegmund, Henry Voelzke, Heyo K. Kroemer. 
Presenter affiliation: Ernst Moritz Arndt University of Greifswald, 
Greifswald, Germany. 
 
 
 
 
 
 
68 
  
Pharmacogenetics of diabetes drugs—Candidate genes encoding 
drug transporters and metabolism enzymes 
Kaixin Zhou, Roger Tavendale, Andrew D. Morris, Colin N. Palmer, 
Ewan Pearson. 
Presenter affiliation: University of Dundee, Dundee, United Kingdom. 
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 1 
EN ROUTE TO THE ERA OF GENOMIC MEDICINE 
 
Eric D Green  
 
National Human Genome Research Institute, National Institutes of Health, 
Bethesda, MD, 20892 
 
The Human Genome Project’s completion of the human genome sequence 
in 2003 was a landmark scientific achievement of historic significance. It 
also signified a critical transition for the field of genomics, as the new 
foundation of genomic knowledge started to be used in powerful ways by 
researchers and clinicians to tackle increasingly complex problems in 
biomedicine. To exploit the opportunities provided by the human genome 
sequence and to ensure the productive growth of genomics as one of the 
most vital biomedical disciplines of the 21st century, the National Human 
Genome Research Institute (NHGRI) is pursuing a broad vision for 
genomics research beyond the Human Genome Project. This vision includes 
facilitating and supporting the highest-priority research areas that 
interconnect genomics to biology, to health, and to society.Current efforts in 
genomics research are focused on using genomic data, technologies, and 
insights to acquire a deeper understanding of biology and to uncover the 
genetic basis of human disease. Some of the most profound advances are 
being catalyzed by revolutionary new DNA sequencing technologies; these 
methods are already producing prodigious amounts of DNA sequence data, 
including from large numbers of individual patients. Such a capability, 
coupled with better associations between genetic diseases and specific 
regions of the human genome, are accelerating our understanding of the 
genetic basis for complex genetic disorders and for drug response. 
Together, these developments will usher in the era of genomic medicine.  
 
 
 
 2 
PHARMACOGENETICS / GENOMICS: PAST, PRESENT AND 
FUTURE 
 
Michel Eichelbaum  
 
Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, 
70376, Germany 
 
Genetic factors have been suggested depending on the drug to account for 
20 to 95 % of the variability in drug disposition and effects. The best 
recognized examples of genetic polymorphisms that influence drug 
response in humans are highly penetrant monogenic traits of drug 
metabolizing enzymes (DME). Inherited difference in a single gene of DME 
has such a profound effect on the pharmacokinetics of a drug resulting in 
more than a 100 fold difference in systemic drug exposure with clinically 
important effect on drug response. Loss of function of DME genes have 
been identified as mechanisms of severe and life-threatening toxicity. 
Examples are CYP P450 and thiopurine-S-methyltransferase deficiency 
where case report and case control studies have demonstrated that the high 
systematic drug exposure associated with loss of function allele translate 
into differences in response and toxicity. Gene duplication as it has been 
demonstrated for CYP2D6 has been identified as a mechanism of poor 
treatment response. In the case of prodrugs loss of function alleles are 
predictive for non-response. Examples include tamoxifen, a drug used for 
the treatment breast cancer, where carriers of loss of function alleles have a 
poorer clinical response with respect to time to recurrence and disease free 
survival. In the case of clopidogrel the antiplatelet effect is mediated by a 
metabolite which is formed by the polymorphic CYP2C19. A major 
limitation in implementing pharmacogenetic testing in the clinical setting 
has been the lack of clinical trial demonstrating that such testing can 
improve drug therapy by reducing toxicity and increasing efficacy. 
 3 
AN INTEGRATIVE GENOMICS STRATEGY TO ELUCIDATING THE 
COMPLEXITY OF DRUG RESPONSE  
 
Eric E Schadt  
 
Pacific Biosciences, Chief Scientific Officer, Menlo Park, CA, 94025 
 
Drug response can be considered as a complex traits like obesity, diabetes, 
and heart disease, where such traits are driven by constellations of genetic 
and environmental (both micro and macro) factors interacting in complex 
ways. However, the genetic and environmental perturbations do not directly 
lead to variations in drug response, but rather impact molecular processes 
that underlie physiological states associated with such responses. Therefore, 
in order to develop a complete understanding of drug response, biological 
systems must be queried in a comprehensive fashion in multiple 
dimensions, and then appropriately integrated so that we understand how 
these different pieces inter-relate to one another to define the molecular 
networks that define physiological states associated with drug response. 
Focusing on a single dimension, even if done in a comprehensive fashion, 
will not be sufficient to get at a complete understanding of drug response. 
Here I present network-based approaches for integrating large-scale, high 
dimensional data generated in mouse and human populations to construct 
the underlying molecular drivers of disease. By projecting molecular 
signatures from different disease models onto these networks, I demonstrate 
how different subtypes of disease emerge. By matching the networks 
underlying these subtypes to drugs that perturb such networks, we can 
achieve a better understanding of response both in terms of efficacy as well 
as adverse events. 
 4 
DEVELOPMENT OF MULTI-SNP PREDICTIVE MODELS AND 
CHARACTERIZATION OF PERFORMANCE METRICS 
 
Scott L Marshall, Jared R Kohler, Laura B Gillis, Christina M Bromley  
 
BioStat Solutions, Inc., 114 South Main Street, Suite 002, Mt. Airy, MD, 
21771 
 
Development of predictive DNA biomarkers in pharmacogenomic (PGx) 
studies presents a challenge in not only how to construct a classifier under 
real-life limitations but also how to assess the performance of the classifier 
under these settings. Consider a genome-wide association study that yields 
multiple findings of interest. The predictive ability of any single nucleotide 
polymorphism (SNP) alone is driven by three main factors: (1) response 
rate (2) effect size and (3) variant allele frequency. In traditional 
classification problems the sensitivity and specificity are primarily driven 
by the underlying performance of the diagnostic tool (which in theory can 
be improved); however, development of a SNP classifier is primarily 
limited by the frequency of the variant in the population. Given a moderate 
effect size for a treatment with reasonable efficacy and irrespective of 
variant allele frequency, it can be demonstrated that jointly maximizing the 
sensitivity and specificity at levels deemed clinically meaningful (e.g. > 
75%) is impractical. Alternatively, positive predictive value (PPV) and 
negative predictive value (NPV) are two performance metrics that are less 
impacted by the variant frequency and under similar conditions may 
provide a more meaningful assessment of clinical utility. While these 
performance metrics in general are commonly accepted, there is no 
consensus best approach for the construction and characterization of the 
predictive model. Here, we suggest an approach to overcome the limitations 
of single SNP predictors by combining the information across multiple 
SNPs with small to moderate effects using supervised principal components 
analysis (PCA) which may improve performance metrics. 
 5 
SYSTEMS (PATHWAY) BIOLOGY IN PHARMACOGENOMICS 
RESEARCH: A HIGHLY SCALABLE BAYESIAN NETWORK 
MODELING APPROACH 
 
Andrei S Rodin1, Grigoriy Gogoshin1, Stephen T Turner2, Julie A Johnson3, 
Arlene Chapman4, Eric Boerwinkle1  
 
1University of Texas - Houston, Human Genetics Center, Houston, TX, 
77225, 2Mayo Clinic, Nephrology and Hypertension, Rochester, MN, 
55905, 3University of Florida - Gainesville, Pharmacotherapy and 
Translational Research, Gainesville, FL, 32611, 4Emory University, Renal 
Medicine, Atlanta, GA, 30322 
 
 
“Systems biology” data analysis and modeling methods (primarily the 
Bayesian Network (BN) modeling) are becoming increasingly important for 
reverse-engineering the interplay of gene variation and other variables 
contributing to inter-individual differences in response to drug treatment. 
We will present a novel BN modeling strategy that takes advantage of (1) 
highly optimized numerical libraries, (2) efficient memory utilization to 
prevent possible memory overflows (into “virtual” memory), (3) iterative 
search algorithms that allow for easy parallelization, (4) cumulative 
bootstrap technique to evaluate the robustness, and (5) a prototype Bayesian 
Dirichlet metric evaluation engine. The main advantages of this new 
strategy are drastically increased scalability (up to 100,000s single 
nucleotide polymorphisms (SNPs) and other variables), robustness (via 
improved search convergence) and ability to incorporate different metrics, 
search algorithm variations, and prior expert knowledge “on the fly”. We 
will then present the results of the application of this novel BN modeling 
methodology to both the candidate gene and GWAS pharmacogenomics 
datasets (blood pressure response to a thiazide diuretic). We will close by 
discussing the issue of the trade-off between scalability and model 
expressiveness in general terms, and how it applies to the systems biology 
approach to the analysis and interpretation of the pharmacogenomics data.  
 6 
SYSTEMS CHARACTERIZATION OF DRUG COMBINATION 
THERAPIES IN A MOUSE MODEL OF METABOLIC SYNDROME 
 
Marijana Radonjic1, Marjan van Erk1, Robert Kleemann2, Teake Kooistra2, 
Lars Verschuren1, Peter Y Wielinga2, Ben van Ommen1  
 
1TNO Biosciences, Physiological Genomics, Zeist, 3704 HE, Netherlands, 
2TNO Biosciences, Vascular and Metabolic Disease, Leiden, 2333 CK, 
Netherlands 
 
The multifactorial nature of metabolic syndrome and associated pathologies 
represents a major challenge for designing optimal treatment strategies. To 
experience health benefit, patients often require a drug combination therapy 
which targets multiple disease endpoints. In addition to beneficial effects of 
such drug combinations, polypharmacy may also increase a risk of adverse 
side effects.  
 
To explore the global effects of single cholesterol-lowering drugs and to test 
if effects of drug combinations may be predicted from the effects of the 
single compounds in the drug mix, we analysed hepatic transcriptome of 
ApoE3Leiden mice that were fed high-cholesterol atherogenic diet 
supplemented either with rosuvastatin, ezetimibe or a combination of these 
two compounds. Understanding the global genome-wide effects of single 
drugs and ability to predict efficacy and safety of their combinations will 
provide evidence-based rationales for designing optimal 
polypharmacological treatments, tailored to meet individual patient’s needs. 
 7 
GENETIC VARIATION IN THE TGF-Β SIGNALING PATHWAY IS 
ASSOCIATED WITH RESPONSE TO PLATINUM-BASED 
CHEMOTHERAPY AND OVERALL SURVIVAL IN OVARIAN 
CANCER PATIENTS 
 
Michelle A.T. Hildebrandt1, Xia Pu1, Larissa Meyer2, Carol Etzel1, Jie Lin1, 
Dong Liang3, Karen Lu2, Xifeng Wu1  
 
1University of Texas MD Anderson Cancer Center, Dept. of Epidemiology, 
Houston, TX, 77030, 2University of Texas MD Anderson Cancer Center, 
Dept. of Gynecologic Oncology, Houston, TX, 77030, 3Texas Southern 
University, Department of Pharmacy and Health Sciences, Houston, TX, 
77004 
 
The TGF-β signaling pathway has been shown to play a role in the 
development and progression of ovarian cancer, as well as patients’ 
response to chemotherapy. However, there is little information regarding 
the effect of common, germline genetic variation within this pathway on 
clinical outcomes for ovarian cancer patients. In this study, we took a 
pharmacogenetics approach and genotyped 218 single nucleotide 
polymorphisms (SNPs) in TGF-β pathway genes in 319 non-Hispanic 
Caucasian ovarian cancer patients. These genotypes were then analyzed for 
response to platinum-based chemotherapy and overall survival. Fourteen 
variants were associated with response, of which eight predicted a favorable 
response for those carrying variant genotypes. The most significant finding 
was for SMAD9:rs9576129 associated with a 55% decreased risk of a poor 
response to therapy (OR:0.45, 95%CI:0.26-0.80). For overall survival, 15 
significant associations were identified among seven pathway genes. This 
included two SNPs in BMP1 that were also associated with response to 
therapy: rs3857979 and rs4075478. Individuals carrying two variant alleles 
of these SNPs were at increased risk for both poor response (OR:1.90, 
95%CI:1.04-3.48 and OR:2.39, 95%CI:1.17-4.89, respectively) and survival 
(HR:1.80, 95%CI:1.23-2.91 and HR:1.89, 95%CI:1.22-2.91, respectively). 
Significant gene-gene interactions were also observed for overall survival 
which identified subgroups of patients with dramatically different risks of 
dying (P for trend:5.4x10-5) and median survival times (P-value:1.5x10-5). A 
significant dose response between number of pathway risk genotypes and 
survival was evident (P for trend:3.40x10-10). Patients with 8 to 13 risk 
genotypes had a median survival time of only 26.8 months compared to 
over 97 months for those with 1 to 5 risk genotypes (P-value:5.3x10-8). 
These results provide evidence that genetic variation within this important 
pathway modulates clinical outcomes in ovarian cancer patients and may 
help to individualize treatment to optimize response and prognosis. 
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IDENTIFYING QUANTITATIVE TRAIT GENES FOR IN VITRO DRUG 
TOXICITY USING HIGH-CONTENT SCREENING 
 
Oscar Suzuki1, Natasha Butz1, Brian Steffy1, Bethany Parks2, O. Joseph 
Trask2, David Scoville1, Amber Frick1, Daniel Crona1, Russell Thomas2, 
Tim Wiltshire1  
 
1UNC Eshelman School of Pharmacy, Pharmacotherapy and Experimental 
Therapeutics, Chapel Hill, NC, 27599-7361, 2The Hamner Institutes for 
Health Sciences, Center for Genomic Biology and Bioinformatics, Research 
Triangle Park, NC, 27709-2137 
 
Pharmacogenetic studies have successfully identified genetic variants that 
contribute to variation in drug response, but it is still a complex and 
challenging task to identify the genetic components of response to drugs 
across the human genome. Despite limitations, there is a pressing need to 
identify genetic components that contribute to the efficacy and toxicity of 
drugs across a wide spectrum of agents. We have proposed that using an 
alternative model population approach will provide many underlying 
mechanisms and pathways that are implicated in drug activity and 
responses. We have developed a platform of in-vitro assays using 
embryonic fibroblasts from genetically well-defined mouse strains which 
enables us to evaluate cellular toxicity effects of current and novel drug 
therapy agents. Here, we present results obtained using this strategy to 
identify genes and gene pathways that underlie susceptibility to cellular-
level adverse drug reactions. We have screened 75 drugs and environmental 
toxins using high-content imaging to assess specific cell-health status 
phenotypes (nuclear changes, membrane permeability, mitochondrial 
membrane potential and cytochrome c localization). The cellular responses 
from 32 inbred mouse strains were used in genome-wide association 
analyses to identify quantitative trait loci (QTL) underlying the toxicity 
variations. This strategy has led to reproducible identification of QTLs, 
allowing a hypothesis-free identification of candidate genes. Although no 
targets have been fully validated yet, we discovered a number of genes that 
potentially affect the measured drug toxicity phenotypes. Gene-set 
enrichment analysis of the candidate loci suggests an over-representation of 
genes involved in cell-cycle regulation. Genes were selected and prioritized 
for validation based on network analysis, expression in mouse embryonic 
fibroblasts and statistical significance of the observed association. 
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Background: We evaluated variation in hormonal pathway genes in a homogenous 
population of prostate cancer patients receiving ADT, with the overall goal of 
identifying single nucleotide polymorphisms (SNPs) associated with treatment 
response duration. TagSNPs in androgen biosynthesis genes (belonging to the C4 Δ 
pathway, C5 Δ pathway, C21 CYP pathway and the alternate “Backdoor pathway” 
for androgen synthesis) and androgen metabolism pathway genes were identified 
using HapMap phase I+II, NIEHS and Seattle SNP databases. A total of 84 genes 
were included.  
 
Methods: To capture common genetic variation, tagSNPs with predetermined minor 
allele frequency (MAF) >5% were targeted using Illumina GoldenGate assay. 
Germline DNA from 338 advanced prostate cancer patients were submitted for 
genotyping. All patients had received and failed ADT. Time to ADT failure was the 
primary endpoint. Patient samples with <98% call rate, incomplete clinic data were 
excluded, leaving 304 samples for subsequent analysis. After filtering out SNPs with 
<5% MAF, <98% call rate and <0.0001 Hardy-Weinberg chi-square p-value, 747 
SNPs were used towards final analysis with response to ADT.  
 
Results: Of the genes analyzed for association with duration of response to ADT, 
TRMT11 (tRNA methyltransferase 11 homologue) was strongly associated with 
ADT response (p<0.0008; adjusted p-value for FDR-0.068). This remained 
significant after evaluating the gene without adjustment for age and Gleason score 
(p-value = 0.001264 and FDR=0.014045). Of four TRMT11 SNPs analyzed 
(rs1268121, rs2326215, rs6569442, rs6900796) with progression time on ADT, two 
(rs1268121, rs6900796) were highly significant for duration of ADT response. An 
overall protective effect was observed in the presence of 0,1 or 2 alleles for these 
SNPs with response duration ranging between 3.08 years to 5.86 years. Four 
additional genes showed moderate association with ADT response (0.025≤p-
value≤0.07) including another methyltransferase, PRMT3 with 2 of the 20 SNPs 
analyzed significantly associated with ADT response each having a protective effect 
(rs11025588 (p=0.0127) and rs11025592 (p=0.0009)). Additionally, three other 
genes (WBSCR22, SLC7A6OS, and LOC390956 with significant association to ADT 
response (p=0.0648, 0.0545, and 0.0312 respectively).  
 
Conclusions: Variation in methyl transferase metabolic activity in hormonal 
pathway genes are strongly associated with ADT response duration time. Validation 
of these findings is being attempted in independent datasets of prostate cancer 
patients. Since ADT is a commonly used treatment in prostate cancer, the use of 
predictive biomarkers has a large public health impact in choosing treatments.  
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Background: GENDEP, a European multicentre integrated 
pharmacogenomic study, aimed to identify genomic correlates of 
antidepressant response including ADRs. 
Methods: White European subjects with major depression were treated with 
escitalopram (ESC) or nortriptyline (NOR), in a part-randomised potential 
crossover design, and prospectively rated for clinical response and ADRs 
(Uher et al, 2008; 2009).  
Results: Polymorphisms in SLC6A4 (5-HTTLPR and STin4 not previously 
investigated) interact with stressful life events (SLEs) occurring in the 6 
months prior to treatment to predict response to ESC but not to NOR (Keers 
et al, 2010). Such SLEs were also associated with a higher cognitive 
symptom score and with a greater reduction in this on ESC but not with 
NOR (Keers et al, in press). Converging results from our genetic association 
and genome-wide association analysis (GWAS) indicate that NTRK2 is 
associated with suicidality (Perroud et al, in press). The CYP2D6 ultrarapid 
metaboliser (UM) genotype was associated with a lower dose of both 
antidepressants over the 12-week trial (β=-0.56, 95% CI -0.88 to -0.25 P < 
0.001; Keers et al, 2010). Rodent gene expression analysis and clinical trial 
transcriptomics data point to a role for PPM1A in response to 
antidepressants (Malki et al, under review). GWAS analysis reveals an 
association between rs2500535 in the uronyl 2-sulphotransferase gene and 
response to NOR, while response to ESC was predicted by a marker in 
(IL11) (Uher et al, 2010). Conclusion: Findings which replicate other data 
are emerging, of potential biomarker utility. Funding: GENDEP was 
fundded by the European Commission, Framework 6 Programme (LSHB-
CT-2003-503428), supplemented by the UK NIHR (Biomedical Research 
Centre for Mental Health) and an MRC-GSK tag-on project for GWAS. 
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Mitochondrial diseases are a class of serious, prevalent, phenotypically 
diverse and genetically complex disorders for which few effective 
treatments have been discovered. We present a simple and powerful yeast-
based assay to screen for drugs with the potential to treat human 
mitochondrial diseases that affect ATP synthase. Our method exploits the 
high conservation of mitochondrial function between yeast and human, as 
well as the amenability of the yeast mitochondrial genome to site-directed 
mutagenesis. The latter possibility has enabled the creation of yeast mutants 
corresponding to several point mutations in the ATP6 gene associated with 
NARP (neuropathy, ataxia, and retinosis pigmentosa) syndrome. The 
severity of the phenotypes in yeast and human correlate, demonstrating the 
suitability of yeast as a model of NARP. Our screen identified several 
compounds, each of which are effective only in particular mutants, thus 
providing a good platform to investigate the role of genetic variation in the 
treatment of ATP synthase disorders. One of these compounds rescues, to 
varying extents, virtually every mitochondrial defect measured in one yeast 
model of NARP and is also effective in human cybrids derived from NARP 
patients. These results validate our method as a useful high-throughput 
approach to identify drugs potentially active in the treatment of ATP 
synthase disorders and offer prospects for the development of personalized 
therapeutics for these disorders. 
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Maculopapular exanthema (MPE) is the most common form of hypersensitivity 
reaction to the antiepileptic drug carbamazepine (CBZ). It requires drug 
withdrawal and re-challenge is not recommended as it may lead to more severe 
reactions. Previous pharmacogenetic studies conducted in patients with CBZ-
induced MPE did not demonstrate any strong associations which could be 
replicated by other groups. Given the immune etiology of MPE and the strong 
association between drug-induced hypersensitivity and several genes in the 
MHC region, we have investigated genetic polymorphisms in the entire MHC 
region on Chromosome 6 in two cohorts (discovery and replication cohorts) of 
Caucasian patients with CBZ-induced MPE.  
In total 2961 patients and controls were included into the study. The discovery 
cohort comprised thirty nine patients who experienced CBZ-induced MPE and 
two control groups- CBZ-tolerant patients (n=43) and WTCCC healthy 
individuals (n=2849). Our replication cohort comprised 30 patients identified 
from a randomised controlled trial (SANAD). All patients and controls were 
Caucasians. Genotyping for 1293 SNPs was undertaken using the Illumina 
MHC SNP mapping panel and BeadArray technology. We compared genotype 
frequencies in our patients with GWAS data (using the 1.2 million Illumina 
chip) available at the Wellcome Trust Sanger Institute for all healthy volunteers. 
Replication study genotyping was performed using TaqMan assays and 
KBiosciences genotyping services. SNP genotype frequencies in patients and 
controls were compared with frequencies in the HapMap, dbSNP and WTCCC 
databases. Data analysis was performed using the BeadStudio, Haploview and 
PLINK software.  
Minor allele frequencies (MAF) across the MHC region in our patients were 
similar to frequencies in dbSNP in Caucasian population. We found an 
association between maculopapular exanthema and a SNP in the coding region 
of HLA-C (P=2.2E-9). We confirmed this finding in our replication study and 
performed meta-analysis (pooled odds ratio OR10 (95% CI 5.5 to 18.6).  
In this study we have identified novel candidate genes and validated our 
findings in a carefully selected replication cohort. Whether this SNP is causal 
for CBZ exanthema or merely reflects linkage disequilirium with a causal 
variant is unclear, and will need to be investigated using functional studies.  
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Statins reduce cardiovascular morbidity and mortality in appropriately 
selected patients. However, statin-associated myopathy is a significant risk 
associated with these agents. Recently, variation in the SLCO1B1 gene was 
reported to predict simvastatin-associated myopathy. The aim of this study 
was to replicate association of the rs4149056 variant in SLCO1B1 with 
severe statin-associated myopathy in a cohort of patients using a variety of 
statin medications and to investigate the association with specific statin 
types. We identified 25 cases of severe statin-associated myopathy and 84 
controls matched for age, gender, statin type and dose. The rs4149056 
variant in SLCO1B1 was not significantly associated with myopathy in this 
group as a whole. However, when subjects were stratified by statin type, the 
SLCO1B1 rs4149056 genotype was significantly associated with myopathy 
in patients who received simvastatin, but not in patients who received 
atorvastatin. Our findings provide further support for a role for SLCO1B1 
genotype in simvastatin-associated myopathy, and suggest that this 
association may be stronger for simvastatin compared to atorvastatin. 
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Cytochrome P450 2B6 (CYP2B6) is highly polymorphic and a number of 
functional single nucleotide polymorphisms (SNPs) and haplotypes have been 
reported in different populations. To date little information is available about 
the frequencies and functional consequences of CYP2B6 polymorphisms in 
Latin American populations. We report the frequency and functional 
consequences of CYP2B6 SNPs for the known CYP2B6 substrate, efavirenz 
(EFV), in 219 HIV+ patients recruited at Fundación Arriarán, Chile between 
Sep. and Dec. 2008. EFV plasma concentrations were determined using a 
validated LC-MS/MS assay. All individuals were genotyped for 30 SNPs with a 
minor allele frequency (MAF)>0.05 in the HapMap CEU population at intervals 
of ~1kB across the CYP2B6 locus using the Sequenom iPLEX MALDI-TOF-
based genotyping platform. SNPs with a MAF<0.01 and Hardy Weinberg 
disequilibrium p-value<0.01 were omitted from subsequent analysis. Thirteen 
SNPs passed QC and were carried forward for further analysis. One-way 
analysis of variance (ANOVA) of EFV plasma concentration with genotype for 
individual SNPs indicated statistical significance (p<0.001) for 11/13 SNPs 
within the CYP2B6 gene. The exceptions were rs4802100 (5' upstream) 
(p=0.08) and rs34083050 (Intron 4) (p=0.91). The statistical significance of the 
genotype associations with EFV plasma concentrations ranged from p=4.4x10-8 
(rs227344) to p=3.6x10-22 (rs8192719). Linkage disequilibrium analysis of the 
13 CYP2B6 polymorphisms showed a significant degree of LD, similar to the 
Caucasian population. Pair-wise tagging SNP analysis (R2>0.8) identified 3 
SNPs (rs10403955, rs2279345 and rs8192719) which were representative of the 
11 plasma EFV concentration-associated SNPs. A composite genetic model of 
these 3 high EFV concentration associated alleles was constructed. An 
association between carriers of 4-6 of these alleles and risk of EFV plasma 
concentration > an upper limit for Ctrough of 4µg/ml was identified. 22/38 
individuals with EFV > 4µg/ml possessed 4-6 associated alleles compared to 
4/140 of those with EFV plasma concentration < 4µg/ml. This represents an 
odds ratio of 48.1 (95%CI: 13.5-207.7). The positive predictive value was 
84.6% and negative predictive value was 89.8% with a sensitivity of 57.9% and 
specificity of 97.2%. Our data suggest that the haplotype structure in the 
Chilean Hispanic population is similar to that in Caucasians. Furthermore, a 
number of polymorphisms in the CYP2B6 gene are associated with increased 
plasma EFV concentrations. Further investigation of the functional basis of this 
association is needed. 
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Background  
The biguanide derivative metformin is the first-line oral hypoglycemic drug 
for the treatment of type 2 diabetes. Metformin is a substrate of organic 
cation transporters (OCTs), which mediate drug absorption and elimination. 
The result of studies regarding the effect of polymorphism of OCT2 on 
metformin pharmacokinetic is different by different ethnics. This result 
gives a clue that other transporters’ polymorphism may play an important 
role. This study is aimed to evaluate the associate between Multidrug and 
Toxin Extrusion 1 (MATE1) transporter and metformin pharmacokinetics.  
 
Methods  
Sixteen healthy Koreans were enrolled in a pharmacokinetic study and 
genotyped for SNP of MATE1, rs2289669 and SNP of OCT2, rs316019. 
Subjects received 1000mg metformin on the 1st day and 750mg metformin 
on the 2nd day. Blood for metformin concentration was collected at 0.5, 1, 
1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, and 24 h after 2nd metformin dose. Urine 
collection for metformin concentration was done following time intervals: 
0–4, 4–8, 8–12, and 12–24 h. The pharmacokinetics of metformin were 
compared between the MATE1 genotype groups (GG=3, GA=8, and 
AA=5). OCT2 genotype distribution was not significantly different in each 
group by Fisher’s exact test (p=0.330). Metformin concentrations in plasma 
and urine were determined by LC/MS/MS.  
 
Results  
AUC and Cmax of metformin carrying rs2289669 GA genotype increased 
11% for Cmax (GG vs GA, 1347±21 vs 1500±425 ng/ml, p=0.053) and 
26% for AUC (GG vs GA, 7790±637 vs 9243±2758 ng/ml*hr , p=0.065), 
carrying AA genotype significantly increased 27% for Cmax (GG vs AA, 
1347±21 vs 1706±209 ng/ml , p=0.031) and 37% for AUC (GG vs AA, 
7790±637 vs 10641±2086 ng/ml*hr , p=0.095) compared to those of GG 
genotype. Renal clearance and secretion clearance of metformin was not 
significantly different by MATE1 genotype.  
 
Conclusion  
Our results suggested the association between the genetic polymorphisms of 
MATE1 rs2289669 and the pharmacokinetics of metformin.  
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With the rapid development of sequencing technologies, vast amounts of 
data are being generated at affordable prices. In order for the field of 
pharmacogenomics to reap the benefits of this sequencing era, this excess of 
data will require appropriate analyses. Thus, careful analyses of the 
variation detected in genes of interest is necessary to allow for the 
possibility of personalised pharmacogenetic profiles to become a reality.  
To demonstrate this, we have taken data from the “bushman” data library 
(http://main.g2.bx.psu.edu/library), which contains the genetic variation 
observed in the genomes/exomes of thirteen individuals (four KhoiSan 
individuals, South African Archbishop Desmond Tutu, two Yoruba 
individuals, four Caucasians, including Craig Venter and James Watson, a 
Chinese individual and a Korean individual). From these data, we identified 
the variation present in the top ten PharmGKB pharmacogenetic genes by 
extracting a region corresponding to the “GP Gene Boundary”, as specified 
by the database. Known functional variation was subsequently identified 
through the use of the CYP and UGT1A1 allele nomenclature websites, in 
combination with data obtained from PharmGKB. Additionally, we 
performed Sorting Intolerant from Tolerant (SIFT) analyses to identify non-
synonymous SNPs that were not described in the aforementioned websites. 
Together, these data were utilised to create pharmacogenetic profiles for all 
thirteen individuals.  
From the results generated, we observed that each of the individuals 
possessed a unique combination of variation that has been reported to 
influence pharmacogenetic applications. When comparing the population 
groups, we noted that although there was consistently more variation 
present in African populations, certain variants appear to be population 
specific. Moreover, African individuals, specifically the Southern African 
individuals, exhibited far more novel/uncharacterised non-synonymous 
SNPs than non-African individuals.  
In conclusion, the exciting developments in sequencing technologies need 
to be accompanied with careful analyses. It is important that the poorly 
characterised African populations, especially those residing in Southern 
Africa, benefit from these technologies which are uniquely suited to detect 
the high levels of sequence variation present in these populations. Lastly, 
due to the extensive nature of the sequencing data, these analyses can be 
extended to create a more complete picture for drug response.  
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There is extensive evidence showing that genomic variations affect drug 
toxicity and efficacy, but there is currently no practical means to screen 
candidate drugs in vitro for genome-associated toxicity early in the drug 
development pipeline. We are building an ethnically diverse panel of human 
induced pluripotent stem cell (hiPSC) lines that could be useful for early 
stage toxicology screens. To date, we have derived 25 iPSC lines from a 
multiethnic cohort of healthy individuals, including several Caucasians, 
African Americans, a Sudanese and a Yoruba individual. The Yoruba, from 
sub-Saharan Africa, is one of the original four ethnic groups analyzed by 
the worldwide haplotype mapping (HapMap) consortium.  
 
We derived hIPSCs from fibroblasts and keratinocytes obtained from skin 
biopsies and hair samples (outer root sheath of hairs). These primary 
cultures were expanded for cryopreservation and transduced to induce 
pluripotency using four transcription factors. The iPSCs were subjected to a 
standard set of assays to confirm that they were typical pluripotent stem 
cells and that the exogenous reprogramming factors had been silenced. 
These assays included immunocytochemistry for pluripotency-associated 
proteins such as OCT4/POU5F1, RTPCR for the exogenous genes, and 
genome-wide gene expression profiling. SNP genotyping was used to 
examine genomic integrity, confirm the ethnicity of the cell lines, and 
identify the  
CYP variants and HLA haplotype of the cells. 
 
Since ninety percent of drug metabolism occurs in the liver, we are 
developing methods for directing differentiation of iPSCs into hepatocyte-
like cells that can be incorporated into toxicity assays. We have 
differentiated iPSCs by a multi-step protocol, and have obtained cells that 
express typical hepatocyte markers, including ASGR, albumin and 
CYP1A2. Our goal is to test the potential of these cells for predictive 
toxicology screens. 
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We have shown that the tetraspanin CD151 has prognostic value in prostate 
cancer (PCa); patients whose cancer has low expression of CD151 have 
better prognosis than those with high levels1. We are now interested in 
CD151’s role in PCa as a motility and metastasis promoter and whether 
inhibition of CD151 results in reduced progression of PCa. Human PCa cell 
lines LNCaP and PC3 were used in cell migration and invasion assays. The 
motility and invasiveness of wild-type LNCaP (low endogenous level of 
CD151) vs. CD151 transfected LNCaP cells and PC3 (high endogenous 
CD151) vs. CD151 knock-down PC3 cells (KD PC3) was analyzed. 
LNCaPs transfected with CD151 showed increased motility and invasion 
compared to control LNCaPs (P<0.05), while KD PC3 cells demonstrated 
reduced motility and invasion compared to control PC3s (P<0.05). Paired 
primary and secondary PCa generated using a SCID mouse model bearing 
implanted human PCa cell lines are also being examined for expression of 
CD151. More recently we have conducted in silico screening with 
compounds predicted to bind the large extracellular domain of CD151, and 
found that a number of these compounds possess in vitro and vivo 
properties in inhibiting PCa progression. Stratification of PCa patients with 
higher levels of CD151 may thus enable more tailored approaches to anti-
metastatic therapeutics of this common and often unpredictable malignancy.  
1 Ang J et al. Cancer Epidemiol Biomarkers & Prevention (2004) 13: 1717-
21  
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Although P2Y12 has a significant role in normal hemostasis and 
thrombosis, no genetic study has been described about the association 
between P2Y12 variants and the extent of ADP-induced platelet activation 
in the Korean population. The expression levels of two reference sequences 
of P2Y12 mRNA transcripts (variants 1 and 2) were examined in the whole 
blood before direct DNA sequencing. The subjects were screened for 
single-nucleotide polymorphisms (SNPs) in P2Y12 by direct DNA 
sequencing (n=50). Frequencies of P2Y12 SNPs, linkage disequilibrium 
blocks, haplotype structures, and haplotype-tagging SNPs were determined. 
The effects of genetic variation in the P2Y12 gene on the extent of ADP-
induced platelet aggregation were studied in healthy Korean men (n=40).  
Variant 2 (NM 176876.1) was the predominantly expressed form in all 
subjects, but variant 1 was also weakly expressed in all cases (n=10). A 
total of 20 SNPs were identified: 2 in exons, 5 in introns, and 8 and 5 in the 
5’-untranslated regions of the known P2Y12 RNA variants 1 and 2, 
respectively. Genetic analysis of the P2Y12 SNPs and haplotypes revealed a 
statistically significant association between P2Y12 haplotype, denoted H3, 
and an increase in the ADP-induced platelet aggregation response relative to 
that for the reference haplotype H1 (P = 0.01). Application of these findings 
to the development of a multivariate model might be useful in explaining 
the variable outcome of antiplatelet drug therapy in Asian populations.  
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Objective: To evaluate the performance of a pharmacometric model for 
warfarin using PC-VPCs in an internal [1] and an external [2] dataset. 
Background: Variability in both pharmacodynamics and pharmacokinetics 
contribute to the pronounced variability in individual warfarin dose 
requirement. We have developed a pharmacometric model for the relationship 
between warfarin dose and anticoagulant response (INR) based on data from 
1426 Swedish warfarin patients [1]. Visual predictive check (VPC) is becoming 
an important diagnostic tool for pharmacometric model evaluation [3]. For data 
collected in studies with adaptive design as for warfarin, prediction corrected 
VPC (PC-VPC) is more suitable [4]. 
Method: The final model and parameter estimates obtained from analyses of 
the Swedish study [1] were used in the internal and external model evaluation. 
PC-VPCs were constructed for the median, 5th and 95th percentile of the 
observed data. Model predictions were based on 100 simulated datasets and 
presented with non-parametric 95% confidence intervals. The procedure was 
repeated on an external dataset derived from a British prospective warfarin 
study [2]. 
Results: The PC-VPC of the internal data did not indicate any major differences 
between observations and model predictions. The PC-VPC of the external data 
showed some evidence of model misspecification with signs of under prediction 
of INR, especially at INR > 3.  
Conclusion: The external evaluation showed some evidence of under prediction 
of INR. The reason for this is currently unknown. Possible reasons for this 
finding include a difference in INR methods (Owren vs. Quick) and/or a 
difference in in vivo behaviour of warfarin tablets from Sweden and UK. 
Acknowledgements: A. Jorgensen and S. Lane at The University of Liverpool 
and S. Bourgeois at Sanger Institute for facilitating access to the British data 
and Prof. A Rane and Dr J Lindh for access to the Swedish data.  
 
References  
[1] A-K Hamberg et al. Clin Pharmacol Ther. 2010;87: 727-34 
[2] A.L Jorgensen et al. Pharmacogenetics and Genomics 2009; 19: 800-812 
[3] M.O Karlsson, N Holford. [www.page-meeting.org/?abstract=1434] 
[4] M Bergstrand, et al [http://www.go-acop.org/sites/all/assets/webform/ 
Poster_ACoP_VPC_091002_two_page.pdf] 
 21 
POLYMORPHISMS OF SENSIBILITY GENES AND THE RISK OF 
RELAPSE OR SURVIVAL TO CHILDHOOD ACUTE 
LYMPHOBLASTIC LEUKEMIA IN KOREA 
 
Sujee Jeon1,2, Sohee Han2, Kyoung-Mu Lee4, Sue K. Park2, Hyo Seop Ahn3, Daehee 
Kang1,2  
 
1Seoul National University College of Medicine, Department of Molecular Medicine 
and Biopharmaceutical Sciences, Seoul, 110-799, South Korea, 2Seoul National 
University College of Medicine, Department of Preventive Medicine, Seoul, 110-
799, South Korea, 3Seoul National University College of Medicine, Department of 
Pediatrics, Seoul, 110-799, South Korea, 4Korea National Open University, 
Department of Environmental Health, Seoul, 110-799, South Korea 
 
Objective  
In our previous genome-wide association study of childhood acute lymphoblastic 
leukemia (ALL), six single nucleotide polymorphisms (SNPs) in 4 genes (i.e., 
HAO1 rs6140264, EPB41L2 rs9388856, rs9388857, rs1360756, C2orf3 12105972, 
MAN2A1 rs3776932) were strongly associated with childhood ALL risk. In a 
subsequent study, we evaluated whether those SNPs are associated with recurrence 
or death of ALL among Korean children.  
Methods  
Incident childhood ALL cases (n=50) and non-cancer controls (n=50) frequency-
matched by age and sex, were recruited from three teaching hospitals in Seoul 
between 2003 and 2008. The blood samples were genotyped using Affymetrix SNP 
Array 6.0 platform. ALL risks were estimated as odds ratios (ORs) and 95% 
confidence intervals (CIs) using unconditional logistic regression analysis adjusted 
for age and birth weight. The false discovery rate (FDR) was used for adjusting 
multiple tests.  
For the selected SNPs that were strongly associated with childhood ALL risk, risk of 
ALL was estimated for the cases with or without recurrence or death, respectively. 
The difference of survival function between the two groups was evaluated by 
logrank sum and Wilcoxon-Gehan test.  
Results  
When we estimated the risk about the selected SNPs, the results showed decreased 
risk about SNP in MAN2A (OR=0.03, 95% CI = 0.00-0.35; OR = 0.15, 95% CI = 
0.05-0.48; with and without, respectively), and increased risk in HAO1 (OR = 5.28, 
95% CI = 0.93-30.11; OR = 8.14, 95% CI = 2.57-25.81; with and without, 
respectively) in both groups of cases. But SNP in C2orf3 showed decreased (OR = 
0.11, 95% CI = 0.03-0.35) and SNPs in EPB41L2 showed increased risk (OR = 
28.97, 95% CI = 5.34-157.20) in only cases that without recurrence or death. 
However, when the difference of survival function between two groups was 
estimated, the results were not statistically significant (P > 0.05).  
Conclusion  
Although we conducted subsequent study to indentify that whether previously 
selected SNPs would modify the recurrence or death of childhod ALL, the results 
were not statistically significant.  
Keywords  
childhood acute lymphoblastic leukemia (ALL), single nucleotide polymorphism 
(SNP), relapse, survival 
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Brain-derived neurotrophic factor (BDNF) is a candidate molecule for 
influencing the clinical response to antidepressant treatment, especially to 
citalopram, an antidepressant of selective reuptake inhibitors (SSRI) class. 
The aims of this study were to determine the relationship between the 
Val66Met polymorphism in the BDNF gene and the response to 
escitalopram, another SSRI antidepressant, in patients with major 
depressive disorder (MDD). Fifty seven Korean patients with MDD were 
enrolled and had treated with escitalopram at dose of 5–40 mg/day. Clinical 
symptoms were evaluated using the HAM-D scale at baseline and after 1, 2, 
4, and 8 weeks of treatment. The genotype and allele frequencies were 
compared according to the response and remission status using multiple 
logistic regression and the difference of % decline of HAMD scores by 
treatment between genotypes was analyzed using type III generalized linear 
model. The proportions of M allele carriers were 81.6% and 83.8% in 
responders at 4 weeks and at 8 weeks, respectively, which were higher in 
non-responders at each corresponding time points (P=0.005 and P = 0.013). 
The percentile decrease of HAMD scores was significantly larger in M 
allele carriers than those in patients possessing VV genotype at 4 weeks of 
treatment (P = 0.019). In addition, the proportion of M allele carriers was 
84.6% in remitter at 4 weeks, which was significantly higher than 64.5% in 
non-remitter (P = 0.038). These results suggest that BDNF V66M affect the 
therapeutic action of esciatlopram in MDD, and that genotypes of BDNF 
V66M may be a genetic marker for predicting the response to escitalopram 
treatment.  
 
 
This study was supported by a grant from the Korea Health 21 R&D 
Project, Ministry of Health and Welfare, Republic of Korea (03-PJ10-
PG13-GD01-0002).  
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Background: TPMT (thiopurine S-methyltransferase) methylates and thus 
inactivates thiopurine drugs such as azathioprine, 6-mercaptopurine and 6-
thioguanine, which are widely used to treat inflammatory bowel disease and 
childhood acute lymphoblastic leukemia. Genetic alterations in TPMT gene 
directly affect the metabolism of such drugs, causing side effects including 
bone marrow toxicity, hepatotoxicity and pancreatitis. PCR-direct 
sequencing method is a gold standard for TPMT genotyping, but it is time 
consuming and expensive. In Korean population, mostly *3C variants 
(c.719A>G) have been reported with incidence of about 0.3-7.6%, therefore 
full sequencing is not ecconomical for TPMT genotyping. Herein, we 
developed and validated a real-time PCR-based method for TPMT 
genotyping.  
Methods: SNP genotyping methods were developed under the real-time 
PCR platform using allele specific primers and 5’ nuclease probes. Three 
important SNPs for TPMT gene (c.238G>C, c.460G>C, and c.719A>G) 
were genotyped based on the differences in Ct (cycle threshold) in the real-
time PCR system. Each reaction was confirmed by PCR-direct sequencing 
method. In addition, automatic interpretation algorithm was developed to 
display genotypes at each site.  
Results: The validity of amplification reactions was assessed based on the 
difference in Ct (ΔCt) for the reactions targeting two different alleles at 
each SNP site. For each SNP site, homozygote specimens showed ΔCt 
greater than 2.0 and heterozygote specimens showed ΔCt smaller than 2.0. 
All these results were concordant with those confirmed by PCR-direct 
sequencing method. Overall turnaround time was around 2 hours and 24 
genomic DNA specimens could be analyzed simultaneously.  
Conclusions: We developed a real-time PCR based genotyping kit for 
TPMT using allele-specific primers and probes, which produced consistent 
results with those by direct sequencing method. This method is expected to 
be practically applied in the clinical practice to determine the individualized 
dose of thiopurine compounds.  
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Background: Acute generalized exanthematous pustulosis (AGEP) is an 
acute pustular eruption occurring usually after drug ingestion and resolves 
spontaneously after discontinuation. Drug-specific CD4+/CD8+ 
lymphocytes are known to play roles in skin lesions of AGEP, however, 
little is known about pathogenesis or genetic susceptibility of AGEP. 
Objectives: To characterize of clinical disease features of AGEP in Korean 
people and evaluate its association with HLA types. Methods: We reviewed 
AGEP cases retrospectively from the database of the Korean 
Pharmacogenetic Adverse Drug Reaction Research Network. Results: 
Twenty five patients were included with approximately equal gender 
distribution (male 52%) and a mean age of 46.8 years (18-83 years). The 
most common drugs were antimicrobials (50%), NSAIDs (21%) and anti-
tuberculosis drug (18.4%), respectively. In 17 patients, mean latency was 
5.2 days. Most patient recovered without any complication (81.2%). 
Systemic corticosteroid was administered in 70% of patients. HLA analysis 
were done in 20 patients and HLA-B*4402 and C*0501 alleles were found 
in 15% of AGEP patients, which was significantly frequent compared with 
Korean general population (2.5% and 0.6%, respectively) (Odd ratio 6.5 
and 7.8, respectively, both P value< 0.05). Conclusion: Our data suggests 
HLA-B*4402 and C*0501 could contribute to the genetic susceltibility to 
AGEP. 
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The objectives of this study were to identify the genetic variants of 
CYP2C8, analyze CYP2C8 single nucleotide polymorphisms (SNPs), and 
characterize their functional consequences in the CYP2C8 substrate drug 
rosiglitazone in humans. The direct full sequencing of CYP2C8 genomic 
DNA was performed in a Korean population (n=50). A total of seventeen 
CYP2C8 variants including a novel coding variant (E274Stop) were 
identified. The novel CYP2C8 E274Stop variant was assigned as 
CYP2C8*11 by the Cytochrome P450 Nomenclature Committee. Seventeen 
SNPs were used to characterize linkage disequilibrium, haplotype 
structures, and haplotype tagging SNPs. Genotyping for CYP2C8*11 in an 
extended set of Koreans (n=400), Caucasians (n=100), Han-Chinese 
(n=348), Vietnamese (n=100), and African-American (n=93) was 
performed by a newly developed pyrosequencing method. The frequency of 
CYP2C8*11 was 0.3% in Koreans, 1% in Vietnamese, and 0.14% in 
Chinese. However, none of the Caucasians and African-Americans 
contained the CYP2C8*11 allele. Subjects with the CYP2C8*1/*11 
exhibited a higher plasma concentration-time profiles of rosiglitazone 
compared to those of 9 control subjects carrying CYP2C8*1/*1. The AUC 
and Cmax of rosiglitazone in individuals carrying CYP2C8*1/*11 (n=5) 
were 54% and 34% higher compared to the mean values observed in the 
control subjects carrying CYP2C8*1/*1, respectively (P=0.015 and 
P=0.025, respectively). In summary, this is the first report to characterize 
the allele frequency and haplotype distribution of CYP2C8 in a Korean 
population, and provides functional analysis of a new variant CYP2C8*11. 
Our findings suggest that individuals carrying CYP2C8*11, a null allele 
found in Asians only, would have lower activity for metabolizing CYP2C8 
substrate drugs. 
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Background: Tamoxifen metabolism is complex and involve N-
demethylation, aromatic hydrocylation, side chain alpha-hydroxylation and 
N-oxidation. The cytochrome P450 enzymes (CYPs) are involved in the 
metabolism. Tamoxifen is further inactivated by sulphotransferase (SULT) 
1A1 and UDP-glucuronosyltransferases (UGTs). N-Desmethyltamoxifen 
(NDM), a major primary metabolite of tamoxifen, is hydroxylated by 
CYP2D6 to yield endoxifen. Because of its high antiestrogenic potency, 
endoxifen may play an important role in the clinical activity of tamoxifen.  
Method: We conducted a prospective trial in 65 patients with breast cancer 
who were treated with 20mg/d tamoxifen to further understand the the 
relationship between genotypes of these enzyme-encoding genes and the 
plasma concentration of tamoxifen metabolites. Genotyping for CYP2D6, 
CYP3A4, CYP3A5, CYP2C9, CYP2C19, SULT1A1, UGT2B15 and UGT2B7 
were performed using DMET plus array (Affymetrix, CA, USA). Steady 
state plasma concentrations of tamoxifen and its metabolites were 
determined after 8 weeks of tamoxifen treatment, using liquid 
chromatography-tandem mass spectrometry.  
Results: The median and range of plasma concentrations of tamoxifen, 
NDM, 4-hydroxytamoxifen, and endoxifen were 128.0 ng/ml (range, 56.8 - 
289.0), 231.0 ng/ml (range, 97.4 - 623.0), 9.6 ng/ml (range, 2.6 - 19.9), and 
25.5 ng/ml (range, 14.1 - 58.6), respectively. The mean endoxifen plasma 
concentration was significantly lower in CYP2D6 IM genotype group than 
in those of EM genotype group (26.8 ng/ml versus 20.9 ng/ml, P = 0.01). 
Endoxifen/NDM plasma ratios were significantly different between these 
groups (P = 0.0015). NDM levels were affected by CYP2C19 genotype 
groups. Homozygotes with CYP2C19*2 or *3 and patients with 
CYP2C19*2/*3 showed significantly higher NDM levels than wild type or 
heterozygotes (P = 0.01 and 0.02, respectively). Genetic polymorphisms of 
the other genes were not associated with tamoxifen metabolism.  
Conclusion: CYP2D6 genotype are highly associated with endoxifen plasma 
concentration and endoxifen/NDM ratios and may have an impact on the 
response to tamoxifen therapy. CYP2C19 genotype may partially explain 
the wide inter-individual variations in the plasma level tamoxifen 
metabolite.  
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Background: Polymorphisms of theVKORC1 (vitamin K epoxide reductase 
complex subunit 1) and CYP2C9 (cytochrome P450 2C9) genes are the 
most important genetic factors related to dose adjustment of oral 
anticoagulant warfarin. Fast and reliable test method is essential for prompt 
dose adjustment of warfarin to prevent serious hemorrhagic or thrombotic 
complications. Previously, we developed a real-time PCR method for 
VKORC1 and CYP2C9 genotyping. However, interpretation of the real-time 
PCR results is not easy. The aim of this study was to develop and validate 
an automatic interpretation program for real-time PCR results.  
 
Methods: Automatic interpretation logic was devised based on the 
difference in Ct (cycle threshold) and display tabs were added to visualize 
the interpreted results and all the reaction curves of each specimen. Validity 
of real-time PCR and automatic interpretation program was confirmed with 
the 28 clinical specimens whose genotypes had been previously confirmed 
by PCR-direct sequencing method. Real-time PCR was performed with 
previously developed kit (AccuPower® warfarin genotyping kit, Bioneer, 
Daejeon, Korea). Automatic interpretation results were compared with 
those determined by visual inspection of reaction curves and with those 
confirmed by PCR-direct sequencing method.  
 
Results: The algorithm was devised in that difference in Ct smaller than 2 
designates heterozygote and greater than 2 for homozygote. Also all the 
genotyping results were described in standard nomenclature and 
summarized in the reaction summary tab. In addition all the reaction curves 
for six SNP sites (VKORC1 3673A>G, 6484C>T, 6853C>G, 9041G>A; 
CYP2C9 430C>T, 1075A>C) were displayed in one screen, making visual 
confirmation of all the results possible. For all the specimens, automatic 
interpretation, visual inspection of real-time PCR and PCR-direct 
sequencing showed consistent results.  
 
Conclusion: Automatic interpretation program can be a useful component of 
the real-time PCR genotyping system, making the genotyping for warfarin 
dose adjustment faster and more convenient.  
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Objectives: MDR1 plays an important role in the clearance of psychotropic 
drugs and their metabolites from brain tissues. This study aimed to discover 
the association between MDR1 genetic variations and OROS-
methylphenidate (MPH) effects in Korean attention deficit hyperactive 
disorder (ADHD) patients.  
 
Methods: Korean ADHD patients completed four week trial of OROS-MPH 
treatment. They were divided into two groups which are mild and severe 
side effect groups using Barkley stimulant drug side effects rating scale 
(SERS). SNaPShot analysis was performed to genotype several tag SNPs of 
MDR1 from ADHD patient subjects. Association with MPH taking ADHD 
patients was studied using statistical analysis. After that, MDR1 membrane 
vesicle ATPase assay was experimented for comparing rs******* allelic 
differences of MPH transporting activity.  
 
Results: MDR1 tag SNPs were analyzed between mild and severe side 
effect groups of MPH taking ADHD patient subjects. Among tag SNPs, 
specific genotype of rs******* showed significant association with severe 
side effect of MPH (p=0.0028, OR=10.74) in the logistic regression 
analysis. Rs******* specific allele of MDR1 showed the least activity to 
transport MPH than other alleles by vesicle ATPase assay.  
 
Conclusion: The specific genotype of rs******* in human MDR1 gene is 
associated with severe adverse reactions to OROS-MPH treatment in 
Korean ADHD patients. 
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The human drug metabolizing cytochrome P450 (CYP) 1A2, is one of the 
major P450 isoforms contributing by about 5-20% to the hepatic P450 pool 
and catalyzing oxidative biotransformation of up to 10% of clinically 
relevant drugs including clozapine and caffeine. CYP1A2 activity is 
interindividually highly variable and although twin studies have suggested a 
high heritability, underlying genetic factors are still unknown. Here we 
adopted a pathway-oriented approach using a large human liver bank 
(n=150) to elucidate whether variants in candidate genes of constitutive, 
ligand-inducible, and pathophysiological inhibitory regulatory pathways 
may explain different hepatic CYP1A2 phenotypes. Samples were 
phenotyped for phenacetin O-deethylase activity, and the expression of 
CYP1A2 protein and mRNA was determined. CYP1A2 expression and 
function was increased in smokers and decreased in patients with 
inflammation and cholestasis. Of 169 SNPs in 17 candidate genes including 
the CYP1A locus, 136 non-redundant SNPs with minor allele frequency 
>5% were analyzed by univariate and multivariate methods. A total of 13 
strong significant associations were identified, of which 10 SNPs in the 
ARNT, AhRR, HNF1α, IL1β, SRC-1, and VDR genes showed consistent 
changes for at least two phenotypes by univariate analysis. Multivariate 
linear modelling indicated that the polymorphisms and non-genetic factors 
together explained 42%, 38% and 33% of CYP1A2 variation at activity, 
protein and mRNA levels, respectively. In conclusion, we identified novel 
trans-associations between regulatory genes and hepatic CYP1A2 function 
and expression, but additional genetic factors must be assumed to explain 
the full extent of CYP1A2 heritability. 
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Introduction: A novel technology termed "Screen and Insert" (ScIn) 
provide convenient and reproducible ways to isolate stable cell clones in 
which transgene expression is stringently regulated by tetracycline (tet). 
The key to ScIn is a powerful d2EGFP-based screen to identify optimal 
chromosomal loci combined with site specific recombination (SSR) to 
target the insertion of transgenes (Brough et al. 2007).  
Methods and Material: We used multidrug resistance-associated protein 2 
(MRP2), an efflux pump involved in the terminal excretion and 
detoxification of endogenous and xenobiotic organic anions, to evaluate this 
approach.  
Results: Tet-transactivator expressing human fibrosarcoma HT1080 cells 
were transfected with a target construct expressing reporter gene (d2EGFP) 
from a tet-responsive promoter (TRP = TRE + CMVmin) using a lox71 site 
positioned between the TRP and the reporter gene (Brough et al. 2007). A 
clone (Rht14-10) with stringently tet-regulated d2EGFP expression was 
selected for co-transfection with a Cre-expression plasmid and a 
promoterless MRP2-EGFP insertion construct which was linked to a lox66 
site positioned upstream of MRP2 (lox66-MRP2-EGFP.pEGFP-N1). Cre-
mediated recombination between the insertion construct and the integrated 
target construct placed the MRP2-EGFP successfully under the control of 
the TRP. G418 resistant colonies were selected. For further analyses clones 
that had lost cytosolic d2EGFP expression showed a clear MRP2-EGFP 
fluorescence in the plasmamembrane with stringently tet-regulated MRP2-
EGFP expression analysed by FACS and Western Blot. Clones of high 
purity as judged by PCR for correct insertion events were positive in a 
CMFDA and mBCl assay for functional MRP2-EGFP expression.  
Conclusions: The ScIn approach described a highly effective way to 
achieve stringent and reproducible tet-regulated MRP2 gene expression in 
an HT1080 background. The method is particularly attractive for functional 
comparison of gene-variants.  
Acknowledgements: Supported by the German Research Foundation (DFG, 
LA 2406/2-1) and the Robert-Bosch Foundation, Stuttgart, Germany.  
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CYP2C9 single nucleotide polymorphisms (SNPs) are important in safe and 
effective oral anticoagulation with warfarin use.The objectives of this study 
were to determine the distribution of CYP2C9 variants in Koreans and 
investigate their association with warfarin dose requirements in patients 
who received mechanical heart valve replacements (MHVRs). All 9 exons, 
intron–exon junction, and promoter region of CYP2C9 were amplified and 
the amplified fragments were directly sequenced in 50 healthy normal 
Koreans. Additional direct DNA sequencing of the CYP2C9 gene was 
conducted in 36 of the 267 MHVR patients who required low maintenance 
warfarin doses without carrying CYP2C9*3 and VKORC1 1173T 
mutations. The effects of CYP2C9 genetics on warfarin maintenance dose 
was assessed in 267 MHVR patients. Thirty-nine SNPs including seven 
previously unidentified SNPs were identified in 50 Koreans by direct DNA 
sequencing. One of the CYP2C9 haplotypes exhibited an association with 
warfarin low dose requirement. This haplotype consisting of -1565C>T, -
1188T>C, IVS3+197G>A, IVS3-334C>T, IVS3-65G>C, IVS4-115A>G, 
and IVS5-73A>G was found in 15% of 36 MHVR patients who required 
low warfarin doses, while 4% of 50 normal healthy subjects exhibited this 
haplotype. One of the SNPs comprising this haplotype, -1565C>T, 
apparently changed a protein binding pattern as observed in electrophoretic 
mobility shift assay. The haplotype including -1565C>T, -1188T>C, 
IVS3+197G>A, IVS3-334C>T, IVS3-65G>C, IVS4-115A>G, and IVS5-
73A>G seems to be associated with lower warfarin dose requirement and 
this haplotype could be considered in the development of warfarin dose 
prediction model for Asian populations.  
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Background: Systemic approaches are needed to understand how variations in 
the genes associated with absorption, distribution, metabolism, elimination and 
response to opioids can be used to predict clinical outcome. We present 2 cases 
of life threatening opioid-induced respiratory depression in the operating room. 
Case One: The patient had severe respiratory depression following 2 mg of 
subcutaneous morphine on top of intrathecal morphine administered for a 
Cesarean section. The patient had a history of near apnea with one dose of 
codeine/acetaminophen (30mg/500mg respectively), but tolerated 
hydromorphone. Case Two: Life threatening respiratory depression occurred 
following epidural morphine given at standard doses for surgical removal of 
tumor. Post-operatively, the patient needed only 0.6mg total of IV 
hydromorphone over 4 days for pain management.  
Methods: Functional candidate polymorphisms in genes involved in opioid 
metabolism and action pathway (CYP2D6, UGT2B7, ABCB1, OPRM1, COMT) 
were genotyped by using SNaPshot® and TaqMan® Drug Metabolism 
Genotyping assays or by amplifying and re-sequencing the corresponding 
genomic regions.  
Results: Case One: Genotype results revealed this patient had an increased 
propensity to generate active metabolites from both codeine (extensive 
CYP2D6 activity) and morphine (increased UGT2B7 activity) while having a 
functional µ-opioid receptor system. These active metabolites are not generated 
with hydromorphone. Case Two: Collectively, this patient appeared to have 
increased exposure and overall sensitivity to morphine and hydromorphone. 
Decreased ABCB1 efflux transporter activity, in combination with low COMT 
activity associated with increased sensitivity of the µ-opioid receptor system 
may have predisposed the patient to this adverse outcome.  
Conclusions: An opioid pathway pharmacogenetic approach along with clinical 
history may provide insight into severe respiratory depressive events in patients 
who received therapeutic doses of opioids and may be useful information to 
mitigate future adverse events.  
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Adiponectin (Apm1) is an adipocyte-secreted protein and its serum levels 
are decreased in obesity, type II diabetes, and coronary heart disease 
(CHD). Peroxisome proliferator-activated receptor-γ (PPAR-γ), a member 
of the nuclear hormone receptor family is involved in the differentiation of 
adipose tissue. Activation of the PPAR-γ improves insulin sensitivity and 
exerts anti-atherogenic effects. In the present study, we have examined the 
association of SNP 45 T/G of the Apm1 and SNP P12A (C/G) of PPAR-γ 
gene in coronary heart disease patients (n=300) and their age matched 
controls (n=300). Genotyping was done by PCR and RFLP methods.  
Results- For Apm1-45 T/G, the frequency of G allele was 14.6 in cases and 
12.0 in controls, whereas for T allele 88.0 in controls and 85.3 in cases. 5.1 
folds elevated risk of CHD was observed with the GG genotype (OR-5.1, 
95% CI-1.45-17.81;p=0.002). With various risk factors, G allele of Apm1 
was associated with increased risk of developing CHD in patients with 
smoking (OR-2.89, 95% CI-1.52-5.52;p<0.001), alcohol intake (OR-2.14, 
95% CI-1.26-3.63;p<0.01), diabetes (OR-7.72, 95% CI-3.80-
15.72;p<0.001), hypertension (OR-9.50, 95% CI-4.92-18.35;p<0.001), 
mental stress (OR-6.54, 95% CI -3.35-12.77;p<0.001) and familial history 
of CHD (OR-7.47, 95% CI 3.89-14.34;p<0.001). There was marginal 
association of G allele as a risk for CHD in patients with positive central 
obesity (OR-2.08, 95% CI-1.04-4.14;p=0.01).  
For PPAR-γ P12A (C/G) SNP G allele frequency was 50.0 in controls and 
37.5 in cases whereas for C allele 62.5 in cases and 50.0 in controls. The 
GG genotype of PPAR-γ was associated with the lower risk of development 
of CHD hence, has a protective effect against the CHD (OR-0.35, 95% CI-
0.22-0.55;p<0.001). PPAR-γ A12 (G) allele also decrease the risk of CHD 
in patients with risk factors like smoking, diabetes, hypertension, mental 
stress and familial history of CHD. Significant protective effect of GG 
genotype was associated with central obesity (OR-0.35, 95% CI-0.15-0.82; 
p<0.01).  
Conclusion- Our study showed that G allele of Apm1- 45T/G 
polymorphism is associated with elevated risk of development of CHD in 
North Indian population whereas,  
G allele (alanine) of P12A (C/G) polymorphism in PPAR-γ gene is 
associated with low risk of CHD in north Indian population independently 
as well as along with various risk factors.  
Key words SNP; atherosclerosis; CHD; adiponectin; - PPAR-γ  
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Adverse cardiovascular outcomes after surgery are common and a serious 
public health concern. Myocardial infarction (MI) is one of the leading 
causes of postoperative morbidity and mortality. Between 5-6% of patients 
with preexisting coronary artery disease (CAD) suffer from perioperative 
MI, which is associated with a 30-40% mortality rate. 
 
One of the most widely accepted strategies to reduce perioperative MI in 
high-risk patients is the use of β-blockers (class I recommendation 
ACC/AHA 2007 guidelines). Βeta-blockers block the adrenergic response 
and have been shown to reduce cardiovascular risk in many clinical trials. 
However, recent placebo-controlled trials questioned the safety of this 
intervention. The PeriOperative ISchemic Evaluation (POISE) trial found 
that perioperative β-blocker use prevented myocardial infarctions but at the 
expense of a 2-fold increased risk of death and nonfatal stroke.  
 
Ample evidence exists that the efficacy and safety of β-blocker treatment is 
influenced by genetic factors, most prominently in the adrenergic signaling 
pathway and the cytochrome P450 2D6 (CYP2D6) enzyme which 
metabolizes most clinically used β-blockers.  
 
Here, we present GENE-VISION, a substudy of the VISION (Vascular 
Events In Noncardiac Surgery Patients Cohort Evaluation) study 
[clinicaltrials.gov: NCT00512109]. VISION is an international, multicenter 
prospective observational cohort study with a targeted enrollment of 40,000 
patients. As of Sept. 2010, 18,000 patients have been enrolled. 
 
GENE-VISION will investigate of the association between β-blocker use, 
perioperative MI and genetic variation in the adrenergic signaling pathway 
and CYP2D6 enzyme, but more importantly establish a platform for future 
perioperative (pharmaco-)genomic research. 
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Flucloxacillin and co-amoxiclav (a combination of amoxicillin and 
clavulanic acid, commonly known as Augmentin) are beta-lactam 
antibiotics. Despite their efficacy, and in the case of co-amoxiclav broad 
use, both can cause severe drug-induced liver injury (DILI), although with 
rare incidence. Recent genome-wide association studies (GWASs) have 
demonstrated an important role played by genetic risk factors in drug-
specific predisposition of both flucloxacillin and co-amoxiclav-induced 
liver injury. However, the rarity of these adverse drug reactions limits the 
sample sizes that can be collected. This results in studies that are not 
adequately powered to discover genetic risk factors with moderate-to-low 
risk. If such variants are present in functionally related genes, for example 
belonging to a common biological pathway, they might have a detectable 
cumulative effect, allowing the identification of pathways enriched in SNPs 
with nominally significant association to DILI. We describe a novel 
approach to combine the GWAS results with gene pathway information to 
identify aggregated effects of genetic variations. We used data publicly 
available through the International Serious Adverse Events Consortium 
(flucloxacillin: 77 cases / 288 genetically-matched controls; and co-
amoxiclav 212/561). Subjects were genotyped using Illumina 1M or 1M-
Duo BeadChips. Tests of association were carried out for each SNP by 
logistic regression conditioned on known associated SNPs and adjusting for 
the top four principal components to account for population structure. Then, 
we paired SNPs to one or more neighboring genes on the basis of linkage 
disequilibrium (LD) with SNPs within those genes. After sorting genes 
based on the minimum p-value of their paired SNP(s), we evaluated the 
enrichment in higher-ranked genes for 200 Kyoto Encyclopedia of Genes 
and Genomes (KEGG) pathways using Gene Set Enrichment Analysis 
(GSEA). We found 4 and 22 pathways being significantly enriched (p-value 
< 0.05) for flucloxacillin and co-amoxiclav, respectively. The heparin 
sulfate biosynthesis pathway was shared in both analyses with consistent 
large odds ratios, suggesting a common genetic susceptibility to liver 
injuries caused by both drugs. 
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Genotype to phenotype association studies provide one common approach 
to detect genetic variants associated with increased risk to disease or 
specific response to drug’s efficacy or toxicity. While these studies are 
published in the thousands annually, inconsistent results among the studies 
are common. Discrepancies between association studies could be attributed 
to different confounding factors which include issues with sample size, 
statistical power, allelic heterogeneity and population structure.  
 
APOE is associated with cardiovascular and Alzheimer disease and is a 
target for clinical genetic testing. Our analysis of novel deep DNA sequence 
data argues against the use of current APOE tests because it inadequately 
predicts disease risks. The present study deep sequences 3805 bases of the 
APOE gene containing 909 bases of promoter, 2755 bases of the structural 
gene and 141 bases of the 3’flanking region in an Oklahoma population of 
African descent. Included in these data are known functional variations 
within the Apolipoprotein E (APOE) coding region and its regulatory 
elements. Our study reveals previously undetected population structure at 
APOE between American communities of African descent, which questions 
previous treatment of this ethnic group as a single population in genetic 
association studies.  
 
This study concludes that 1) admixed populations, such as African 
Americans, should not be characterized as a single genetic population, 2) 
the evidence for population structure, which may confound disease 
association studies, may only be observed when haplotype data are 
obtained, 3) deep sequencing and haplotype characterization is essential for 
disease association studies where allelic heterogeneity is a concern.  
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Background 
Diminished efficacy of salmeterol for improving asthma control is increased in 
children with asthma homozygous for arginine-16(Arg16) allele of the ADRB2 
gene. Concerns have been raised regarding the efficacy and safety of long-term 
salmeterol use in patients with asthma. We investigated whether there is a 
genotype-specific difference in long-term asthma control with montelukast 
compared to salmeterol in individuals homozygous for Arg16 of ADRB2.  
Methods 
In this pragmatic randomised controlled trial, 62 children with asthma, carrying 
Arg/Arg16 genotype and exacerbation of asthma at least once within the 
previous year, were randomly assigned to receive Flixotide® (fluticasone 
propionate) via accuhaler (Diskus) dry powder inhaler device plus oral 
montelukast (Group I); or Seretide® (salmeterol plus equivalent dose of 
fluticasone) via accuhaler dry powder inhaler device plus placebo for 
montelukast (Group II). No effort was made to blind the prescribed inhaler. The 
primary end point was school absence, prospectively measured as individual 
events over the period of one year.  
Results 
No significant difference was observed in school absences (p=0.097) between 
the treatment groups. The use of reliever medication was significantly decreased 
in Group I compared to Group II (p= 0.004). Total exacerbations were reduced 
in Group1 compared to Group 2 (p=0.049). Self-reported symptoms were 
significantly improved in Group I compared to Group II (morning cough 
p=0.018; morning wheeze p=0.001; morning dyspnoea p=0.008; night wheeze: 
p=0.004; night dyspnoea: p=0.001). A significant improvement in quality of life 
as per the Juniper pediatric asthma quality of life questionnaire was observed in 
Group I compared to Group II (activity limitation score (p=0.004), symptom 
score (p=0.009), emotional function score (p=0.002) ). 
Conclusion 
In individuals homozygous for Arg16 of the ADRB2 locus, montelukast is an 
effective step up medication compared with salmeterol. Montelukast, as an 
asthma controller added on to inhaled steroid, improved asthma symptoms and 
quality of life, while reducing the use of reliever medication, in comparison to 
salmeterol. A larger randomised controlled trial is required, comparing asthma 
control with salmeterol versus montelukast in the genotypic sub-groups in 
ADRB2, and to explore the cost-effectiveness of genotype-specific controller 
therapies in children with asthma.  
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Antiepileptic drug-related adverse drug reactions (ADRs) are a major 
reason of discontinuation of treatment. Skin rash is one of these ADRs, 
which is showing mostly unpredictable and belongs to idiosyncratic type of 
ADRs. To find new genetic targets of dermatologic reactions to 
antiepileptic drugs, a whole genome-based SNP analysis was performed 
using Affymetrix 5.0 SNPchip containing 500,568 SNPs and samples from 
132 patients treated with antiepileptic agents showing skin rash and those 
from another 132 patients showing no signs of dermatologic side effects. 
The SNP selection criteria were 1) minor allele frequency > 0.05, 2) 
genotyping success rate > 0.98, and 3) P > 0.001 in the Hardy-Weinberg 
Equilibrium test from QQ plot. The P values of association between these 
SNPs and antiepileptic agent-related skin rash were calculated in dominant, 
recessive, and co-dominant mode. A total of 21 SNPs showed with P values 
under 0.000001. Among these, 11 SNPs were in intragenic regions while 
the remaining 10 SNPs were in intergenic regions. The present study 
suggests that some genetic polymorphisms are highly related to the 
dermatologic side effects of antiepileptic agents. Our findings also 
encourage further studies, particularly confirmatory studies with larger 
samples, to validate and analyze the association between these SNPs and 
antiepileptic agent-related ADRs. (This study was supported by grant 
A030001 from the Korea Health 21 R&D Project, Ministry of Health & 
Welfare, Korea) 
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Epigenetic modification plays an important regulatory role in diseases such 
as cancer. While bisulfite sequencing is the most powerful method to study 
DNA cytosine methylation,approximately 99% of cytosine bases are 
converted to uracil thus creating essentially a 3 base bisulfite-converted 
genome that has less signature than a 4 base genome and is more difficult to 
map against with short reads. Traditional approaches to map the bisulfite-
converted tag to both a bisulfite-converted reference and an unconverted 
reference can lead to loss of information when mapping reads with a 
moderate number of methylated cytosines. For example a read that has 6 
methylated and 6 unmethylated bases would not map to either reference 
when mapped allowing up to 5 mismatches. In order to enable accurate 
mapping to the highly redundant bisulfite-converted genome,we have 
developed a mate-pair scheme in which only one mate-pair tag is bisulfite 
converted while the other tag remains unconverted. The adapters and non-
converted tag are protected via incorporation of 5-methyl-cytosine,which is 
resistant to bisulfite conversion.We used this protocol to make a mate-pair 
library from a human MCF-7 cell line. The non-converted sequence 
provides an “anchor” in the genome and facilitates the identification and the 
methylation status of the bisulfite-converted tag. This approach reduces 
mis-mapping since the anchor sequence regulates the mapping of the 
bisulfite-converted tag and allows the non-anchored tag to tolerate more 
mismatches and thus map more of the moderately methylated tags and open 
a window to these previously difficult to obtain regions. This novel 
technique has the potential to provide a routine and reliable method for 
hypothesis free genome-wide methylation detection. Studying the role of 
methylation on gene expression will provide useful information on the role 
of epigenetic mutations in human breast cancer.  
The SOLiD instrument is For Research Use Only. Not intended for any 
animal or human therapeutic or diagnostic use. 
 40 
OPIOID PATHWAY PHARMACOGENETIC ANALYSIS OF 
NEONATAL OPIOID TOXICITY FOLLOWING MATERNAL USE OF 
CODEINE DURING BREASTFEEDING 
 
Johanna Sistonen1,2, Parvaz Madadi3, Colin J Ross1,2, Jong W Lee1,2, 
Mojgan Yazdanpanah1,2,4, Bruce C Carleton2,5, Gideon Koren3, Michael R 
Hayden1,2  
 
1Centre for Molecular Medicine and Therapeutics, University of British 
Columbia, Vancouver, BC, Canada, 2Child and Family Research Institute, 
University of British Columbia, Vancouver, BC, Canada, 3Clinical 
Pharmacology and Toxicology, Hospital for Sick Children, Toronto, ON, 
Canada, 4British Columbia Clinical Genomics Network, University of 
British Columbia, Vancouver, BC, Canada, 5Pharmaceutical Outcomes and 
Policy Innovations, University of British Columbia, Vancouver, BC, 
Canada 
 
Background: Codeine is globally one of the most widely used opioid 
analgesics for the treatment of mild to moderate pain. However, there are 
substantial interindividual differences in codeine response and toxicity. In 
North America codeine is routinely prescribed for maternal post-partum 
pain. It has been previously shown that maternal use of codeine during 
breastfeeding can be associated with central nervous system (CNS) 
depression in neonates. The identified genetic risk factors, CYP2D6-related 
ultra-rapid metabolism in combination with increased UGT2B7 activity, 
however, explained only 12% of the neonatal toxicity cases. We 
hypothesized that additional variations in genes involved in codeine and 
morphine metabolism and action pathway contribute to the risk of CNS 
depression in neonates whose mothers were using codeine and 
breastfeeding. 
Methods: 26 mothers with infants exhibiting signs of CNS depression 
related to maternal codeine use during breastfeeding (cases) and 86 mothers 
of asymptomatic infants (controls) were identified. We genotyped 26 
functional candidate polymorphisms in five genes involved in opioid 
metabolism and action pathway (CYP2D6, UGT2B7, ABCB1, OPRM1, 
COMT) by using SNaPshot®, TaqMan® Drug Metabolism Genotyping and 
Copy Number assays. Associations of single genetic markers, haplotypes, 
and non-genetic factors with the adverse outcome were investigated by 
regression and haplotype analyses. 
Results: Extensive conversion of codeine into the pharmacologically active 
morphine and morphine-6-glucuronide metabolites (p=0.02) and decreased 
activity of the efflux transporter ABCB1 (p=0.0001) were significantly 
associated with neonatal CNS depression. Maternal codeine dose was also 
significantly higher in cases as compared to controls (p=0.004). 
Conclusions: Genetic and non-genetic factors can be used to predict 
response to codeine and to prevent potentially life-threatening CNS 
depression. 
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Various genotype-based dosing algorithms and tables are available to 
predict personalized doses for the anticoagulant drug warfarin. These dose 
prediction methods take into account whether a patient has variants in the 
CYP2C9 and VKORC1 genes that affect warfarin sensitivity, as well as 
other patient characteristics, such as age, sex, and body mass. Our goals 
were to: 1) compare the accuracy and properties of six such genotype-based 
algorithms and a genotype-based dosing table to each other and to 5 mg 
fixed-dose and empirical approaches to dosing, and 2) characterize the 
outliers resulting from inaccurate predictions. Residual blood specimens 
from a hospital clinical laboratory were obtained from male patients (n = 
150) on stable maintenance doses of warfarin. DNA was extracted and 
genotyped for variants of the CYP2C9, VKORC1 and CYP4F2 genes. 
Clinical/demographic information and actual (i.e.empirical) warfarin 
initiation doses were obtained from the electronic medical record. Warfarin 
doses were predicted by the genotype-based approaches and compared 
retrospectively to the patients’ actual stable maintenance doses. The 
accuracy of the predicted doses was assessed by a variety of measures. We 
found that the strength of correlation (R2) between actual and predicted 
stable maintenance doses varied and fell into three tiers: 0.56-0.58 (for four 
algorithms), 0.41-0.47 (for two algorithms and the dosing table), and 0.10 
(for empirical dosing). No genotype-based dose approach was better than 
empirical dosing in predicting starting doses within 0.5 mg of the stable 
maintenance dose. However, most genotype-based approaches increased the 
percentage of patients with starting doses within 1 mg and within 2 mg of 
the stable dose, and reduced the percentage whose doses differed by 2 mg 
or more from the stable dose, i.e. large outliers. All genotype-based 
approaches unexpectedly created new large outliers, but eliminated more 
than they created. Two algorithms yielded more large outliers than the 
others; one predominantly underestimated the doses (88%; 28/32), while the 
other predominantly overestimated (83%; 25/30). About 5% (8/146) of 
patients were large outliers with all algorithms. A CYP4F2 variant and less 
common CYP2C9 variants (*5, *6, and *11) did not account for most 
outliers. Some dosing approaches were more effective for low-dose 
CYP2C9-VKORC1 genotypes, others for intermediate dose genotypes, 
while all were equally effective for high-dose genotypes. Our results reveal 
that several genome-based dosing approaches outperform the others. 
 42 
GENETIC VARIATION OF MEMBRANE-BOUND CATECHOL-O-
METHYLTRANSFERASE AND SUSCEPTIBILITY TO 
SCHIZOPHRENIA AND ANTIPSYCHOTIC INDUCED ABNORMAL 
INVOLUNTARY MOVEMENTS IN AN AFRICAN POPULATION 
 
Galen E Wright1, Britt I Drögemöller1, Lize van der Merwe2,3, Liezl Koen4, 
Craig J Kinnear5, Dana J Niehaus4, Louise Warnich1  
 
1Stellenbosch University, Genetics, Stellenbosch, 7600, South Africa, 
2Medical Research Council, Biostatistics Unit, Tygerberg, 7505, South 
Africa, 3University of the Western Cape, Statistics, Bellville, 7535, South 
Africa, 4Stellenbosch University, Psychiatry, Tygerberg, 7505, South 
Africa, 5Stellenbosch University, Molecular Biology and Human Genetics, 
Tygerberg, 7505, South Africa 
 
The catechol-O-methyltransferase (COMT) gene is an attractive candidate 
for schizophrenia-susceptibility as it encodes a catabolic dopamine enzyme 
and is located in an area of the genome that has been linked to 
schizophrenia on numerous occasions. The enzyme exists as two distinct 
isoforms, with the membrane bound protein (i.e. MB-COMT) being 
predominantly expressed in the brain. Since African populations remain 
underrepresented in psychiatric genetic and pharmacogenomic research, we 
performed a genetic association study on this gene in the local Xhosa 
population with regards to susceptibility to schizophrenia and antipsychotic 
induced abnormal involuntary movements.  
 
The spectrum of common DNA sequence variation in the MB-COMT P2 
promoter was determined by resequencing 15 Xhosa schizophrenia samples. 
Fourteen candidate single nucleotide polymorphisms (SNPs) were selected 
by means of a literature search and in silico analyses. Polymorphisms were 
subsequently genotyped in a cohort of 238 Xhosa schizophrenia patients 
and 240 healthy Xhosa controls. Additionally, samples were screened for 
deletions of the COMT gene locus using duplex real-time PCR. Statistical 
analyses were performed with regards to schizophrenia-susceptibility and 
the presence of abnormal involuntary movements, including tardive 
dyskinesia.  
 
Two SNPs in the vicinity of the MB-COMT P2 promoter were significantly 
associated with schizophrenia-susceptibility reduction in the Xhosa cohort. 
These polymorphisms were in high linkage disequilibrium and have 
previously been associated with increased gene expression in vitro, which 
could possibly prevent excessive amounts of dopamine accumulating in the 
prefrontal cortex. No gene deletions were detected in the Xhosa population. 
The data generated by this study indicate that genetic variation of MB-
COMT could be associated with schizophrenia-susceptibility in the local 
Xhosa population and may therefore be one of the genomic loci 
contributing towards schizophrenia-susceptibility in the South African 
community.  
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Warfarin is the most commonly used anticoagulant, yet it remains a very 
challenging and problematic drug to prescribe due to its narrow therapeutic 
index and large interindividual variability in dosing requirements. Genetic 
polymorphisms in two genes, CYP2C9 and VKORC1, have been shown to 
explain over 35% of warfarin dose variability. Several studies have 
described VKORC1 missense mutations in patients resistant to warfarin 
who required higher warfarin doses. To identify rare mutations in the 
VKORC1 gene in our cohort of 70 warfarin resistant patients, sequencing of 
the VKORC1 promoter and exonic regions was performed on the Applied 
Biosystems 3730 sequencer with big dye terminator cycle sequencing kit. 
Warfarin resistance was defined as the requirement of >10mg warfarin per 
day for at least three weeks in the absence of any comedication with 
enzyme inducers and evidence of adherence. Four novel mutations have 
been identified and one of these is located in the VKORC1 promoter region: 
-160G>C. To test whether this promoter variant could lead to changes in 
VKORC1 promoter activity, DNA from patients with the -160 GG or GC 
genotype was PCR-amplified, cloned into the pGL3 vector and transfected 
into HepG2 cells. Dual luciferase assay revealed that the VKORC1 
promoter with the C allele had an 18% increase in activity when compared 
with the G allele. This increase in promoter activity may explain why the 
patient with the -160 GC genotype required higher warfarin doses. Further 
functional work is currently underway to elucidate the roles of the other 
novel mutations identified. 
 44 
THE GENETIC CONTROL OF DRUG RESPONSES 
 
David B Goldstein  
 
Duke University, Center for Human Genome Variation, Durham, NC, 
27708 
 
 
Although pharmacogenetics has, to date, made less of a contribution to the 
personalization of drug use than many had predicted, recent progress 
strongly suggests that we will soon witness a significant acceleration of 
clinically relevant pharmacogenetic discoveries. Here I first review our 
experience of studies of the genetic bases of variable response to treatment 
of hepatitis C. I next use this experience to outline appropriate discovery 
strategies for a variety of pharmacogenetic questions and attempt to identify 
important discovery opportunities. 
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Carbamazepine (CBZ) can lead to various forms of hypersensitivity ranging 
from maculopapular exanthema to severe blistering reactions. A strong 
association has been demonstrated between CBZ-induced Stevens Johnson 
Syndrome (SJS) and the HLA-B*1502 allele on Chromosome 6 in Han 
Chinese, but not in Caucasians. However, to date no association with HLA 
has been demonstrated for carbamazepine-induced hypersensitivity 
syndrome (also known as DRESS) in either Caucasians or Chinese patients.  
In the present study, we have investigated genetic susceptibility to 
carbamazepine-induced DRESS in 4 steps: 1) we performed genotyping for 
1293 SNPs across the MHC region on chromosome 6 using the Illumina 
MHC SNP mapping panel and BeadArray technology; 2) we undertook a 
genome-wide association study using the Illumina 1.2M SNP chip to 
investigate whether other MHC and non-MHC gene variants are implicated 
in hypersensitivity reactions to CBZ; 3) conducted imputation analysis to 
identify any other SNP associations; and 4) performed sequence based-high 
resolution HLA-typing to identify the HLA marker.  
In total 2913 patients and controls were included in the study. Twenty one 
patients developed DRESS. Two control groups comprised CBZ-tolerant 
patients (n=43) and WTCCC healthy individuals (n=2849). All patients and 
controls were Caucasians. SNP genotype frequencies in patients and 
controls were compared with frequencies in the HapMap, dbSNP and 
WTCCC databases. Data analysis was performed using the BeadStudio, 
Haploview and PLINK software packages.  
Logistic regression analysis in the MHC showed an association between 
CBZ-induced DRESS and several SNPs in the coding region of HLA-A 
(p=4.7E-6). Genome-wide mapping showed a convincing association with 
several SNPs in the same region of the MHC, with genome wide 
significance (10-9). HLA-A sequence-based typing in patients and CBZ-
tolerant controls showed a strong association with one HLA-A allele (OR 
25.8 (95% CI 3.0 to 226.4, p=0.0003).  
We have identified, in a multiple step approach, an association between one 
HLA-A allele and CBZ-induced DRESS in Caucasians, the first time this 
has been done in this ethnic group and with this phenotype. Functional 
studies are being performed to establish whether the HLA marker is the 
causal variant.  
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Background Anthracycline-induced cardiotoxicity (ACT) is a serious 
adverse drug reaction of cancer treatment limiting its use as an effective 
chemotherapeutic agent and contributing to substantial morbidity and 
mortality in childhood cancer survivors due to subsequent cardiomyopathy. 
High cumulative doses are known to increase cardiotoxicity risk, though 
genetic factors are also likely to be important given the high inter-individual 
variability in tolerated doses.  
Methods We carried out a comprehensive genetic association study using 
approximately 3,000 single nucleotide polymorphisms (SNPs) in 220 key 
drug biotransformation genes in an initial cohort of 156 children treated 
with anthracyclines in Vancouver, with replication in a second cohort of 
188 children treated in pediatric oncology units across Canada as part of the 
Canadian Pharmacogenomics Network for Drug Safety (CPNDS).  
Results We identified a highly significant association of ACT with a coding 
variant in a transporter gene (P = 1.0x10-4). We found further evidence (P < 
0.01) for association with risk and protective variants in other genes 
including several other transporters. Combining these multiple variants with 
important clinical risk factors into a single predictive model, we were able 
to classify patients into 3 risk groups. The positive predictive value in the 
high risk group was 75% with almost 40% of patients developing serious 
cardiotoxicity within the first year, 24% of whom went on to develop 
congestive heart failure (CHF). In contrast, very few patients in the low risk 
group experienced ACT, none of whom developed CHF, with a negative 
predictive value of 96%.  
Conclusions We have identified multiple genetic variants associated with 
ACT. Combined with clinical risk factors, they can be used to identify high-
risk patients who can then be provided with safer, alternative treatment 
options. 
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Copy number variants (CNVs) account for a major proportion of human 
genetic polymorphism and it has been suggested that they may play an 
important role in genetic susceptibility to human disease. The WTCCC 
undertook a large, direct, genome-wide study of association between CNVs 
and 8 common diseases. Using a purpose-designed array we typed ~19,000 
individuals into distinct copy number classes at over 3,000 CNVs, including 
an estimated 50% of all common CNVs larger than 500 base pairs. We will 
discuss some of the experimental and analytical challenges in CNV studies 
and sources of artefactual associations, along with the results of the study. 
Although we saw some instances of CNV associations with the diseases 
studied, common CNVs in general, and those showing association in our 
study, tend to be well-tagged by SNPs, and we conclude that common 
CNVs that can be typed on existing platforms are unlikely to be a major 
source of the missing heritability for common diseases. There would seem 
to be analogous, or even more formidable, challenges in performing reliable 
inferences for disease association at rare CNVs.  
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Background. The relationship between genetic variations in androgen 
biosynthesis (SRD5A) and inactivating (UGT2B) genes and the risk of 
biochemical recurrence (BCR) after prostatectomy remains an unexplored 
area.  
 
Methods. We studied a cohort of 526 men with organ-confined and locally 
advanced cancer with a median follow-up of 7.4 years. A total of 19 htSNPs 
distributed across the SRD5A 1 and SRD5A 2 genes were studied as well as 
copy number variations in UGT2B17 and UGT2B28 genes. htSNPs were 
selected with a strategy to maximize gene coverage and to reflect 
adequately the Caucasian haplotype genetic diversity. The htSNPs strategy 
allowed us to study 109 genetic variations in both SRD5A genes. Each 
genetic variation found to be associated with BCR was further analyzed by 
Kaplan-Meier analysis and Cox regression model. 
 
Results. After adjusting for all clinico-pathologic risk factors, we found a 
strong association between the risk of BCR and 7 SNPs in SRD5A genes. 
The combination of 2 SNPs respectively in SRD5A 1 and SRD5A 2 were 
highly favourable, reducing drastically the risk of BCR for carriers of 3-4 
alleles (HR=0.34; 95% CI=0.18-0.64; P=9x10-4). Other variations 
specifically in the SRD5A 2 gene were associated with an increased rate of 
BCR, namely the coding SNPs rs523349 (V89L) with a HR of 2.12 (95% CI, 
1.21-3.75; P=0.009) and reaching a relative risk of 4.97 when combined 
with deleted copies of UGT2B genes (95% CI, 2.38–10.36; P=2x10-5). 
BCR-free survival rate was reduced to 27% in patients with this 
combination of unfavourable genotypes compared to 75% for patients with 
favourable genotypes (P=7x10-6).  
 
Conclusion. Inherited polymorphisms in the SRD5A and UGT2B genes are 
independent predictors of biochemical recurrence after radical 
prostatectomy. With further validation, these findings may ultimately help 
refine our ability to identify individuals at low or high risk of cancer relapse 
after RP, beyond known prognostic variables, and for whom a more 
personalized approach might optimize outcome, especially in the era of 5α-
reductase inhibitors therapy. 
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CALGB 40101 is an ongoing Phase III trial comparing the efficacy of 
standard therapy cyclophosphamide and doxorubicin (AC x 4 or 6 cycles) 
with single agent paclitaxel (P x 4 or 6 cycles) as adjuvant therapy for 
breast cancer in women with 0-3 positive axillary lymph nodes. AC and P 
are associated with significant toxicities, with peripheral neuropathy being 
the major toxicity of P. As part of this study, we have collected germline 
DNA for a pharmacogenetic GWAS to identify genetic predictors of 
toxicity. Germline DNA was isolated from 1040 patients on the P arm of 
CALGB 40101 and genotyped using the Illumina 610-Quad platform. 
Following QC analysis, genotypes were available for 520,679 SNPs. A 
principal components analysis identified 859 genetic Europeans that were 
the focus of this analysis. Since both the timing and degree of toxicity are 
important clinical considerations, sensory PN was modeled using two 
complementary approaches. A time to event approach defined “event” as 
first Grade 2 or higher sensory PN and “time” as the total prior drug 
exposure. The maximum grade of sensory PN occurring during treatment or 
follow-up was modeled using ordinal logistic regression and total prior drug 
exposure as a covariate. One SNP surpassed the level of genome-wide 
significance and three of the other top ten hits were in genes implicated in 
congenital or experimental PN. Patients carrying a variant FZD3 allele had 
a decreased risk of P-induced PN (p=3.1x10-9). FZD3 is a Wnt signaling 
receptor affecting axonal growth and guidance. Variant ephrin receptor 
(EPHA5) and ephrin binding protein (GRIP1) alleles were also associated 
with increased risk of P-induced PN (p=9.6x10-7, 4.3x10-6). Risk alleles 
were identified in two genes implicated in congenital PN, FGD4 (p=2.6x10-
6) and NDRG1 (p=5.2x10-5). These findings are further supported by a 
significant enrichment for SNPs annotated in neuronal development 
pathways. Heritable variation in FZD3, EPHA5, GRIP1, FGD4 and NRDG1 
may modify a patient’s risk of developing P-induced sensory PN. If these 
findings are replicated, the ability to identify patients at risk of this common 
toxicity could influence the choice of adjuvant breast cancer therapy. 
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Background: Inter-individual variation in genetic background may influence 
response to chemotherapy and overall survival for advanced stage non-
small cell lung cancer (NSCLC) patients.  
Methods: To identify genetic variants associated with overall survival in 
these patients, we conducted a genome-wide scan to identify variants 
associated with survival for 327 advanced stage Caucasian NSCLC patients 
who received platinum-based chemotherapy with or without radiation at 
MD Anderson Cancer Center. A fast track replication was performed for 
315 patients from the Mayo Clinic followed by a second validation at the 
University of Pittsburgh in 420 cases enrolled in the Spanish Lung Cancer 
Group PLATAX clinical trial.  
Results: A SNP in the chemokine-like receptor 1 (CMKLR1), rs1878022, 
was identified as significantly associated with overall survival. It conferred 
a 1.59-fold increased risk of dying (95% CI: 1.32-1.92, P = 1.42x10-6) in the 
MD Anderson discovery population. This highly significant increase in risk 
was replicated in the PLATAX clinical trial (HR: 1.23, 95% CI: 1.00-1.51) 
and in combined Mayo Clinic and PLATAX validation (HR: 1.19, 95% CI: 
1.03-1.37). Meta-analysis of these three patient populations demonstrated a 
highly significant 1.32-fold increase in risk (95% CI: 1.18-1.48, P = 
1.42x10-6). Another candidate SNP, rs10937823, was significant in the MD 
Anderson and Mayo Clinic populations with a combined risk increase of 
1.82-fold (95% CI: 1.42-2.33, P = 1.73x10-6), but did not replicate in the 
PLATAX clinical trial (HR: 0.96, 95% CI: 0.69-1.35).  
Conclusions: These results may have significant clinical potential in helping 
to achieve personalized chemotherapy for NSCLC patients. 
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Introduction: NSABP P-1 and P-2 are the two largest trials of tamoxifen 
and raloxifene for breast cancer prevention. We performed a genome-wide 
association study (GWAS) with DNA from subjects in P-1 and P-2 who 
developed breast cancer inspite of SERM therapy to identify SNPs and 
genes associated with the development of breast cancer in this setting.  
Methods: A nested, matched case-control GWAS was performed that 
included 592 cases who developed invasive breast cancer or ductal 
carcinoma in situ, matched with 1171 controls who did not. GWAS 
genotyping with the Illumina 610-Quad chip and CYP2D6 genotyping were 
performed. Functional genomic studies involved siRNA knockdown and 
overexpression in cultured cells, followed by qRT-PCR and Western blot 
analyses.  
Results: 547,356 SNPs were used in the GWAS analysis, with correction 
for population stratification. The top 10 SNPs with p-values that ranged 
from 2.12E-06 to 7.28E-06 on chromosomes (Chr) 3, 4, 9, 13, and 16 were 
identified by conditional logistic regression—with rs8060157 on Chr 16 
having the lowest p-value (OR=0.70, MAF in controls =0.47). Following 
imputation and fine mapping, functional genomic studies focused on five 
Chr 16 SNPs (p-values 2.12E-06 to 3.70E-06), all in ZNF423, a gene 
encoding a putative zinc finger protein. Incubation of U20S cells stably 
transfected with estrogen receptor (ER) α with 0.1 nM estradiol (E2) 
showed that expression of ZNF423, BRCA1 and BRCA2 was induced by 
estrogen exposure. However, in lymphoblastoid cell lines stably transfected 
with ERα, estrogen-dependent expression of all 3 genes occurred only with 
wild type (WT), but not variant ZNF423 SNP sequences, while blockade of 
ERα with ICI-182,780 or with 4-hydroxytamoxifen prevented induction 
with WT sequences, but resulted in allele dose-dependent increases in 
BRCA1 and BRCA2 expression after ER blockade in cells with variant SNP 
sequences—results compatible with the “protective” effect of the variant 
SNPs during clinical SERM therapy.  
Conclusions: This GWAS of subjects enrolled in the NSABP P-1 and P-2 
trials identified SNPs associated with risk for the development of breast 
cancer in high risk women treated with SERMs. The SNPs identified in 
ZNF423 were associated with differential E2-dependent induction of 
ZNF423, BRCA1 and BRCA2. These common ZNF423 SNPs were 
associated with both reduced breast cancer risk during SERM therapy and 
with differential estrogen-dependent expression of BRCA1 and BRCA2.  
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BACKGROUND: We sought to identify novel genetic markers for treatment 
related outcomes in patients with hypertension and coronary artery disease 
(CAD).  
 
METHODS: The Illumina Custom Cardiovascular Array, which contains about 
50K SNPs in candidate genes and pathways for cardiovascular, inflammatory, 
and metabolic phenotypes, was genotyped in 1460 patients with hypertension 
and CAD from the INVEST-GENES which randomized patients to an atenolol-
based β blocker (BB) strategy or verapamil SR-based calcium channel blocker 
(CCB) strategy with trandolapril and/or hydrochlorothiazide added if necessary 
for BP control. Primary outcome was defined as first occurrence of death, 
nonfatal myocardial infarction (MI) or nonfatal stroke. Initial association 
analysis was performed in each treatment strategy with PLINK, under an 
additive genetic model. Treatment interaction analyses were performed with 
SAS.  
 
RESULTS: 45,319 SNPs met quality control procedures and were retained for 
analysis. Three SNPs in SELE, selectin E precursor, were among the top hits in 
the CCB strategy. SNPs rs3917410, rs3917452, and rs5361 were associated 
with the primary outcome (P=3.32x10-5, 3.54x10-5, and 3.77x10-5, respectively, 
with Odds Ratio (OR) (95% Confidence Interval (CI)) = 2.46 (1.61-3.76), 2.44 
(1.60-3.74), and 2.44 (1.60-3.73), respectively). All three SNPs are in high LD. 
rs5361 encodes for a missense mutation (Ser128Arg), and the Arg128 allele has 
been previously associated with higher risk for CAD in multiple populations. 
However, rs5361 showed no evidence of association with the primary outcome 
in the BB strategy (P=0.99, OR (95% CI) = 1.21 (0.66-2.20)). After examining 
SNP x treatment interaction, a significant risk was observed in patients with one 
or two copies of the Arg128 allele in the CCB strategy (interaction P=0.008).  
 
CONCLUSIONS: While these findings require replication, these results suggest 
that in addition to the previous associations with CAD, rs5361 in SELE 
influences cardiovascular outcomes in a treatment specific manner in patients 
with hypertension and CAD. It is unclear whether CCBs increase risk in carriers 
of the Arg128 allele, or if the allele’s risk is reduced by β-blocker treatment.  
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The Critical Assessment of Genome Interpretation (CAGI) is a community 
experiment to evaluate computational methods for predicting the 
phenotypic impacts of genomic variation. Participants will be given 
unpublished genetic variants and will make predictions of resulting 
phenotype. These predictions will be objectively assessed against 
experimental characterizations. The long-term goal for CAGI is to improve 
the accuracy of phenotype and disease predictions of rare variants in clinical 
settings.  
 
CAGI, which is based on the framework of the long-running Critical 
Assessment of Structure Prediction (CASP), will entail four phases:  
* Unpublished associations of genotypes with molecular, cellular, or 
organismal phenotypes will be collected by the organizers from 
experimental and clinical labs  
* Participants will make computational predictions of phenotypes from 
provided genotypes  
* Experimental and clinical scientists will assess predictions  
* A community workshop will be held to disseminate results and evaluate 
our collective ability to make accurate and meaningful predictions.  
 
From this experiment, we expect to understand the diversity of mechanisms 
of genome variation, identify bottlenecks in genome interpretation, inform 
critical areas of future research, and connect researchers from diverse 
disciplines whose expertise is essential to methods for genome 
interpretation. Preliminary data sets we have been offered include 
enzymatic activity of human metabolic enzymes, segregation of rare 
variants identified in from resequencing in cancer cases and controls, 
phenotypic impact of variants of a checkpoint protein, clinical phenotypes 
associated with complete genomes, and molecular mechanisms underlying 
GWAS disease associations. For more information, see 
http://genomecommons.org/cagi/. 
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In order to address the inter-individual variability observed in the 
pharmacokinetic response to many medications, we have created a broad-
based custom genotyping panel that interrogates variation present in ~180 
key genes involved in the Absorption, Distribution, Metabolism and 
Excretion (ADME) of many therapeutic agents. The assay consists of 
~3,000 SNPs and is composed of two types of variation, published markers 
that alter gene function (~360 SNPs) and haplotype tagging markers that 
define blocks of linkage disequilibrium across ADME genes. After several 
phases of development and optimization, the panel has a conversion rate of 
close to 100% with the flexibility to add additional marker content. 
Moreover, the accuracy of the panel has been validated using ~50 HapMap 
samples of known genotype and genotyping results in 24 samples have been 
compared across two commercial ADME products; DMET-Plus 
(Affymetrix) and Veracode ADME Core Panel (Illumina). To test the utility 
of the ADME genotyping assay in a research project, we screened 150 
extensively characterized liver samples from the Institut für klinische 
Pharmakologie (IKP) in Stuttgart. The livers have been previously tested 
using several genomic approaches such as whole-genome genotyping, gene 
and protein expression and selected ADME enzymatic activity. 
Additionally, there is also extensive clinical and demographic information 
for each sample including disease status and concomitant medications. To 
date we have identified a considerable number of statistically significant 
genotype/phenotype associations between our ADME genotyping results 
and gene expression (eQTLs). Furthermore, we have reproduced the 
identification of several previously published eQTLs for our ADME genes. 
We are currently testing some prioritized targets for further functional 
characterization. In addition, we were able to make correlations between 
ADME genes variation, ADME protein expression and ADME enzymatic 
activity. With the demonstration of the usefulness of our panel to identify 
new and previously identified phenotype/genotype correlations in the IKP 
liver samples, we believe that our ADME panel would have broad 
applicability to any study or clinical trial that would benefit from the 
evaluation of an extensive list of ADME genes. 
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Chemotherapeutic-induced cell cytotoxicity as measured by cell growth 
inhibition in HapMap lymphoblastoid cell lines (LCLs) has been shown to 
be heritable and amenable to genetic dissection. As a result, LCLs have 
served as a model system to identify genetic variants associated with 
chemotherapeutic toxicity in patients. However, cytotoxicity is a broad 
phenotype encompassing both apoptotic and non-apoptotic avenues of cell 
death. Apoptosis is considered a more refined phenotype that may be a 
better representation of cell death for some tissues (and some tumors). To 
evaluate whether chemotherapeutic induced apoptosis is heritable and how 
this phenotype compares to cytotoxicity, we measured caspase 3/7 activity 
along with cell growth inhibition in LCLs derived from Caucasian 
monozygotic twins, siblings and unrelated individuals. Drugs included 
platinum agents, cisplatin and carboplatin; antimetablites, Ara-C, 
capecitabine, pemetrexed; and a mitotic inhibitor, paclitaxel. Apoptosis was 
evaluated 24 hours following exposure to increasing concentrations of each 
drug. Among these six drugs, paclitaxed induced the greatest degree of 
apoptotic response followed by Ara-C with capecitabine and pemetrexed 
producing the lowest apoptotic response among the six drugs. Interestingly, 
chemotherapeutic induced apoptosis was significantly correlated with cell 
growth inhibition at low concentrations of Ara-C, capecitabine and 
paclitaxel but not higher concentrations of these three drugs implying that 
the route of cell death to these three drugs treatment may vary depending on 
the drug concentration with higher concentrations going through non-
apoptotic pathways. This is consistent with our data demonstrating genetic 
variants differ for high versus low concentrations of drug. The variance 
between each twin set (intra-twin variation) was significantly lower than the 
variance among the unrelateds across all six drug treatments. For example, 
the variance among the twins after 20μM capecitabine treatment is only 
28% of the variance among the unrelated. This suggests that anticancer 
agents induced apoptosis is a heritable trait. Our results demonstrate the 
value of evaluating apoptosis as a separate phenotype in the identification of 
genetic variants associated with chemotherapy.  
(* contributed equally)  
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Deep sequencing and tiling array analyses of transcriptomes obtained from 
various cells and tissues of multiple organisms reveal that information 
stored in DNA sequences is complex, layered and compartmentalized. It is 
complex based the multiple types of novel RNAs continuing to be identified 
and that serve specified functions. Genetic information is also layered 
because within a given length of genomic sequence multiple RNAs can be 
produced serving different functional roles. Finally, it is compartmentalized 
because cells shuttle specific RNAs to designated compartments within 
cells after they are made. This compartmentalization provides an added 
level of control of expression and function. Multiple examples of RNAs that 
illustrate these characteristics of complexity and multifunctional layering 
will be described. One example is the transcripts enriched within sub-
compartments within the nucleus of cells. These RNAs have specific 
properties and their isolation speak to a poorly understood mechanism of 
post transcriptional regulation of expression. Their functional roles will be 
discussed.  
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Due to the introduction of effective combination risk-adapted therapies the 
treatment of pediatric acute lymphoblastic leukemia (ALL) has greatly 
improved in the past four decades. Nevertheless, therapy resistance in a 
significant number of children is a major obstacle to successful treatment 
whereas intensive treatment has also important drug side effects. 
Pharmacogenetic studies that have been conducted in ALL identified 
genetic variations in several drug pathways that may contribute to 
variability in treatment responses. Asparaginase (ASP) which depletes cells 
of essential amino acid asparagine is one of the important components of 
ALL treatment. Clinical studies have shown a direct relationship between 
outcome and dose intensity. Nevertheless, a number of patients fail to 
respond well to treatment with ASP. Several studies conducted in vitro have 
shown that asparagine synthetase (ASNS), an enzyme that is critical to the 
biosynthesis of asparagine, plays a role in mediating drug resistance. The 
data obtained by microarray profiling using ASP-sensitive and -resistant 
ALL cells pointed to several other proteins that may, in addition to ASNS, 
be of relevance to resistance to ASP treatment. ATF5 stimulated ASNS 
expression in response to asparagine starvation and the increase in 
expression of arginosuccinate synthase 1 (ASS1) was also found. No data 
are yet available whether polymorphisms in these genes may affect the 
outcome of childhood ALL. Here we report the analysis of the 
polymorphisms in ASNS, ATF5 and ASS1 genes and their association with 
ALL outcome. Eleven polymorphisms located in the regulatory and coding 
region of these genes were analyzed in 270 children diagnosed with ALL 
and CHU Sainte Justine, Montreal and treated with the Dana-Farber Cancer 
Institute ALL Consortium protocols DFCI 87-01, 91-01, 95-01 or 2000-01. 
The association between obtained genotypes and event free survival (EFS) 
and overall survival (OS) was performed. Additionally, the same analyses 
were done following stratification by the treatment protocol given the 
differences in the type of ASP and administered dose. After the correction 
for multiple testing, C231T in ATF5 showed highly significant association 
(p<0.001) with reduced EFS in ALL patients treated with DFCI 91-01 
protocol. The C231T substitution is located in 5’UTR of ATF5 gene, 
potentially affecting level of expression. We are currently testing promoter 
activity in relation to the alleles of this polymorphism. 
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Dihydropyrimidine dehydrogenase (DPD) is the key enzyme in the catabolism 
of 5-fluorouracil (5-FU), one of the most commonly prescribed 
chemotherapeutic agents worldwide. However, the importance of 
polymorphisms in the DPD gene (DPYD) for the prediction of severe toxicity in 
5-FU based chemotherapy has been under debate. Early studies estimated that 
around 25% of 5-FU related toxicities are caused by genetic variants in DPYD, 
whereas subsequent studies suggested that the deleterious mutations known so 
far only accounted for a small proportion of severe 5-FU related adverse effects, 
and thus were unsuitable as makers for general pre-treatment testing. Recently, 
however, we identified two novel DPYD-haplotypes (HapB3 and HapB6) 
containing only synonymous and non-coding mutations being significantly 
associated with severe 5-FU toxicity in 111 cancer patients. One of these 
haplotype (HapB3), has recently been found to contain a deep intronic mutation 
(c.1129–5923C>G), which affects pre-mRNA splicing and leads to reduced 
DPD activity. Here, we report the results of a genetic analysis of DPYD in an 
extended population of 243 cancer patients receiving 5-FU-based 
chemotherapy. The significant association of HapB3 with severe toxicity was 
confirmed in the extended data set (p = 0.0018) with a HapB3 frequency of 
9.3% in 43 patients with grade ≥3 toxicities, and 1.8 % in the remaining patients 
(n = 200). This is in agreement with a recently reported retrospective analysis of 
203 cancer patients showing that the HapB3 associated c.1129–5923C>G splice 
mutation was significantly enriched in patients with severe 5-FU toxicity (9.1%; 
66 patients) compared to patients without toxicity (2.2%; 137 patients). Overall, 
we found toxicity-associated DPYD variants (including IVS14 +1 G>A, HapB6 
and c.1679T>G) in 10 (23 %) out of 43 patients with grade ≥3 toxicities, while 
the prevalence of these variants was only 4.5% in patients without toxicities. 
Remarkably, both cases with lethal toxicity were either homozygous for HapB3 
or carrier of the rare HapB6. These results suggest that genetic variants in 
DPYD represent important pharmacogenetic markers for severe 5-FU toxicity 
and that their application in pre-treatment screening needs to be re-considered in 
the light of the discovery of additional functionally relevant DPYD variants 
located outside the coding regions. 
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The recent unmasking of genetics lesions in tumors has optimized cancer 
treatment regimens, specifically with the identification of the presence of c-
ERBB2/neu oncogene amplifications, the BCR-ABL translocations and 
EGFR mutations. It is predicted that in coming years, the hypermethylation 
patterns of particular genes will also predict response to specific treatments. 
The most promising epigenetic candidates to predict pharmacoepigenetic 
response are the DNA repair genes undergoing epigenetic inactivation in 
tumors, such as the 06-methylguanine DNA methyltransferase (MGMT), 
the mismatch repair gene hMLH1, the Werner gene (WRN) or the breast 
cancer susceptibility gene BRCA1. In healthy tissues these enzymes are 
responsible for repairing the DNA damage that occurs during our lifetime 
and prevent the formation of mutations and other type of genomic damage. 
However, in cancer cells they become our terrible foes because they repair 
the DNA damage induced by many used chemotherapy agents, thus, 
generating chemoresistance to drugs. However, there is another side to this 
story: these DNA repair genes undergo hypermethylation-associated 
silencing in a fraction of human tumors that progress with a mutator 
pathway phenotype, but this is also an Achilles’ heel because these 
hypermethylated-malignancies will not be able to repair the DNA damage 
caused by the chemotherapy agent. With the emerging epigenomic 
technologies we now have the techniques that will help address the DNA 
methylation chemoprofiles in an unbiased manner, and complete the 
promising pharmacoepigenetics landscape. 
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Background: Aromatase inhibitor (AI) therapy of estrogen receptor (ER) 
positive breast cancer greatly reduces disease recurrence. However, up to 
50% of post-menopausal women treated with AIs experience new or 
worsening muscle and joint pain (musculoskeletal adverse events, MS-
AEs), and approximately 8% discontinue therapy because of this drug 
reaction. In a previous case-control genome-wide association study 
(GWAS) of DNA samples from the NCIC-CTG-NCI MA.27 adjuvant 
therapy trial of AIs in early breast cancer, we identified four SNPs on 
chromosome 14 that were associated with MS-AEs (Ingle et al., J Clin 
Oncol, in press). Those SNPs had p-values that ranged from 2.23E-06 to 
6.67E-07 and mapped near the 3’-end of the T-Cell Leukemia 1A (TCL1A) 
gene. Therefore, we set out to study the possible role of TCL1A in 
mediating musculoskeletal pain during AI therapy.  
Methods: Functional genomic studies in pursuit of this GWAS SNP signal 
included qRT-PCR using RNA from U2OS cells stably transfected with 
ER(α) or ER(β), siRNA knockdown of TCL1A and other genes, qRT-PCR 
and Western blot analyses, and dual luciferase reporter assays to study NF-
kB transcriptional activity.  
Results: We showed that TCL1A expression was increased by estrogens 
and regulated expression of the interleukin 17 receptor (IL-17RA), IL-17 
and NF-kB transcriptional activity—all markers for joint inflammation. 
Increased TCL1A expression was also associated with the variant SNP 
genotypes in estradiol-treated lymphoblastoid cells stably transfected with 
ER(α). Finally, exposure to estradiol, followed by ER blockade with ICI-
182,780, resulted in greatly increased NF-kB transcriptional activity. These 
studies have linked the variant SNP sequences near TCL1A to drug effect 
and clinical phenotype, in both cases through TCL1A.  
Conclusions: Our case-control GWAS of DNA samples from a large AI 
clinical trial identified 4 SNPs on chromosome 14 located near the 3’-end of 
TCL1A that were associated with AI-dependent MS-AEs. In the present 
functional experiments, we found that estrogen regulates TCL1A and that 
TCL1A regulates IL-17RA and IL-17 expression and suppresses NF-kB 
transcriptional activity. These results provide a mechanistic 
pharmacogenomic explanation of risk for the occurrence of a clinically 
important adverse drug reaction. They may also provide insight into 
estrogen-dependant mechanisms for musculoskeletal pain.  
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Background: The formation of active metabolites during tamoxifen (Tam) 
treatment of early breast cancer is anticipated to be critical for drug efficacy. 
Plasma levels of (Z)-4-hydroxytamoxifen (4-OH-Tam) and (Z)-endoxifen 
(endoxifen) are highly variable and this is attributed to polymorphisms of drug 
metabolizing enzymes. Clinical studies showed a strong relationship between 
cytochrome P450 2D6 (CYP2D6) genotypes and tamoxifen outcome. 
Translation of these findings into clinical practice however requires guidelines 
to personalize endocrine treatment of early breast cancer. Therefore, it is 
important to establish the correlation of steady-state tamoxifen metabolite 
plasma levels and genotypes and moreover, identify other factors potentially 
contributing to this variability. 
Methods: Postmenopausal patients with ER positive breast cancer were 
recruited within an ongoing observational clinical trial (German Study ID 456) 
for the identification of endocrine treatment predictors. Patients were treated 
with 20 mg/d Tam. We quantified Tam, desmethyl-Tam, endoxifen, 4-OH-Tam, 
and 19 other phase I and phase II metabolites by rapid resolution LC-MS/MS in 
plasma of 236 patients. Patients were genotyped for CYP2D6 *3, *4, *5, *6, *7, 
*8, *9, *10, *41; CYP2C19 *2, *3, *17; CYP2C9 *2, *3; CYP 3A5 *3; CYP 
2B6 *6; UGT1A4 *2; UGT 2B7 *2; and UGT 2B15 *2 by Taqman allelic 
discrimination and copy number assays. 
Results: There was an allele-dose dependent relationship between reduced-
function/deficiency CYP2D6 alleles and endoxifen levels (p<10-16). Median 
steady-state endoxifen concentrations were 77.0 nM, 30.8 nM, 13.4 nM and 9.0 
nM for UM, EM, IM, and PM, respectively. 5 of 9 EM patients had endoxifen 
levels similar to those of PM patients (2 of these reported co-medication with 
CYP2D6 inhibitors). With respect to CYP2C9, carriers of reduced function 
alleles showed decreased plasma levels of endoxifen and 4-OH-Tam. No 
correlations were found for CYP2B6, CYP2C19, and CYP3A5 polymorphisms. 
Conclusions: Endoxifen plasma concentrations correlate with genotypes and 
therefore, the CYP2D6 genotype can be used to predict expected plasma 
concentrations. The phenotype prediction benefits from comprehensive allele 
coverage and this should be useful in treatment outcome prediction. CYP2C9 
genotype and co-medication with CYP2D6 inhibitors together with other yet 
unknown factors may also play a role. 
Supported by the Robert Bosch Foundation, Stuttgart, and the BMBF grant 
#01ZP0502, Germany, and the German Tamoxifen and AI Study Group 
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A recent genome-wide association study (GWAS) for urinary bladder 
cancer (UBC) has identified multiple novel genetic risk factors (Rothman 
et. al, in press). One of these factors was an intronic single nucleotide 
polymorphism (SNP) rs11892031 located within the UGT1A locus on chr 
2q37. The human uridine 5’ diphosphate (UDP)-glucuronosyltransferases 
(UGTs) belong to a superfamily of proteins that represent the major 
biochemical mechanism of cellular defense and detoxification of diverse 
endo and exotoxins that can function as carcinogens. UGTs transform these 
compounds into water-soluble glucuronides that are eliminated from the 
body via bile and urine. Genetic variants within UGT1A locus associated 
with decreased activity of UGT enzymes have been previously associated 
with increased risk of different cancers and toxicity of cancer drug 
irinotecan. UGT1A locus represents a cluster of 9 coding and 2 non-coding 
genes that share exons 2-5 and have unique but highly similar exons 1 that 
define substrate specificity. Due to the complexity of the region and ~90-
95% similarity between exon 1 sequences of UGT1A genes, this region is 
poorly represented in public databases (HapMap, 1000 Genomes, dbSNP). 
To ensure specificity of detection, we generated long-range amplicons and 
sequenced all UGT1A exons in HapMap individuals (CEU) and in 44 
bladder cancer patients and identified 25 non-synonymous coding 
variations. All these variations are being genotyped in 1000 bladder cancer 
cases and 1000 controls. Our preliminary analysis identified a risk 
haplotype of several variations previously associated with altered 
detoxification and risk of other cancers, and a novel protective haplotype. 
Both haplotypes are specific for bladder cancer patients with 
previous/current history of smoking, suggesting that UGTs play a 
significant role in detoxification of tobacco-borne carcinogens and risk in 
bladder cancer. 
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Chemotherapeutic agents are used in the treatment of many cancers, yet 
variable resistance and toxicities among individuals limit successful 
outcomes. Understanding the contribution of genetics to chemotherapeutic 
response is key to maximizing drug efficacy and minimizing adverse side 
effects. We used HapMap lymphoblastoid cell lines to measure 
chemotherapeutic-induced cytotoxicity in populations of African descent 
for which there is a disparity in the number of pharmacogenomic research 
studies conducted. We performed genome-wide association studies 
(GWAS) in Yoruba (YRI) and African American (ASW) populations and 
identified SNP predictors of cisplatin, carboplatin, capecitabine, ara-C, and 
pemetrexed-induced cytotoxicity. Traditional GWAS test single markers 
and are powered to detect SNP associations with relatively strong effects, 
but are unable to detect multiple smaller effects working together. We 
found that the chemotherapeutic susceptibility SNPs in the YRI population 
are enriched for expression quantitative trait loci (eQTLs, p<10-3). Most of 
these are trans eQTLs and thus simply examining the region directly 
surrounding a SNP that associates with a phenotype of interest for possible 
functional genes is inadequate. The SNP may be affecting many genes 
across the genome and one gene may be affected by many SNPs across the 
genome. We used a novel approach called functional GWAS (fGWAS) that 
combines multiple SNPs that affect the activity of each gene into one gene-
level test for association with chemotherapeutic response. The functional 
SNP set for a particular gene included any nonsynonymous SNPs within the 
gene and eQTLs associated with the gene in cis or trans. fGWAS in the 
YRI resulted in the genome-wide significant association of 234 genes with 
cisplatin IC50, 81 genes with capecitabine AUC, 64 genes with carboplatin 
IC50, 47 genes with pemetrexed AUC, and 13 genes with ara-C AUC (p<10-
6). Similar fGWAS are ongoing in the ASW. Importantly, by the nature of 
fGWAS, functional information for how these associated genes may be 
acting to affect phenotype is already known and will drive future studies of 
their mechanisms in chemotherapeutic response. 
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Background: Radiation therapy is used to treat half of all cancer patients. 
Response to radiation therapy varies widely among patients. Several clinical 
factors are known to influence radiation response, including radiation dose, 
volume and fraction, but it is also known that genetic inheritance can play 
an important role in variation in radiation response. Therefore, we 
performed a genome-wide association study (GWAS) to identify 
biomarkers to help predict radiation response using 277 ethnically defined 
human lymphoblastoid cell lines (LCLs).  
Methods: Basal gene expression levels and 1.3 million genome-wide SNP 
markers from both Affymetrix and Illumina platforms were assayed for all 
277 human LCLs. MTS assays for radiation cytotoxicity were also 
performed to obtain area under the curve (AUC) as a radiation response 
phenotype for use in the association studies. Functional validation of 
candidate genes, selected from an integrated analysis that used SNP, 
expression and AUC data, was performed with multiple cancer cell lines 
using specific siRNA knockdown, followed by MTS and colony-forming 
assays. Further mechanistic studies were also performed for two candidate 
genes.  
Results: 27 loci, each containing at least 2 SNPs within 50kb with p-values 
<10-4, were associated with radiation AUC. 270 expression probe sets were 
associated with radiation AUC with p<10-3. The integrated analysis 
identified 50 SNPs in 14 of the 27 loci that were associated with both AUC 
and the expression of 39 genes that were also associated with radiation 
AUC (p<10-3). Functional validation using siRNA knockdown in multiple 
tumor cell lines showed that C13orf34 (BORA), MAD2L1, PLK4, TPD52 
and DEPDC1B each significantly altered radiation sensitivity in at least 2 
cancer cell lines. Preliminary mechanistic studies for two candidate genes, 
TPD52 and Bora, demonstrated novel functions of these two genes. TPD52 
is involved in regulation of the NFκB pathway through the regulation of 
IKKγ ubiquitination, while Bora is involved in regulation of DNA damage 
and repair pathways.  
Conclusions: In this study, we identified and functionally validated five 
novel candidate radiation responsive genes. Studies performed with LCLs 
can help to identify novel biomarkers that might contribute to variation in 
response to radiation therapy and enhance our understanding of mechanisms 
underlying that variation.  
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Payer reimbursement policies for pharmacogenomic (PGx) technologies are 
variable, but often do not include coverage because of stated lack of 
evidence of clinical utility. However, evidence thresholds may change as 
the average cost per actionable test result decreases and the possibility of 
‘preemptive’ PGx information becomes a possibility. The strengths and 
weaknesses of current evidence and cost-effectiveness frameworks will be 
presented, and novel approaches using value of information analyses, with 
consideration of PGx vs. non-PGx drug information, will be discussed. 
Specifically, development of recommendations for inexpensive tests that 
fall in the traditional ‘insufficient evidence’ category will be evaluated. 
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Background: It is no longer hypothetical that genomic technologies will 
increase the likelihood that clinically relevant results will be obtained in the 
course of research. This coupled with the NIH GWAS policy suggesting 
that researchers and IRBs consider developing a plan to manage this 
occurrence has moved the controversial issue of return of individual 
research results (ROR) to the forefront of pharmacogenomic research.  
Methods: In-depth interviews were conducted with 31 IRB members and 
staff at 6 US sites. Interviews were conducted in person or by phone, audio-
recorded, and transcribed with individual identifiers removed to protect 
privacy. Coding and content analysis of interview text was performed 
independently by two analysts and compared for consensus. In depth 
analysis was conducted by team review.  
Results: IRB members and staff see returning individual genomic research 
results as a complex issue, especially due to the fast paced, rapidly changing 
nature of the research and their lack of familiarity with genomic research. 
Positions on the issue of ROR were often expressed as being context 
dependent, where variables such as disease type and validity and utility of 
the result both now and in the future must be considered. Conditions for 
returning a genomic result favored a clinical utility perspective, where 
results should have clinical significance, be obtained in a CLIA approved 
lab, be life threatening, and be medically actionable. A personal utility 
perspective, based on respect for the research subject and opportunity for 
non-medical interventions was also considered by some as a condition for 
return. All participants expressed the need to honor a subject’s right to 
know and right not to know results. Participants expressed different views 
on the IRB’s role in ROR: active involvement or oversight of the process of 
decision-making.  
Conclusions: In the context of genomic research, a complex web of tensions 
and thresholds for uncertainty exist among different IRB members and staff. 
ROR blurs the line between genomic research and clinical care and thus 
IRB responsibility related to this issue. This is complicated by the varying 
levels of knowledge/comfort with reviewing such protocols. Consideration 
of these findings can inform the development of policy to guide IRBs and 
researchers in decision-making related to ROR. 
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The Pharmacogenomics Knowledge Base (PharmGKB: 
http://www.pharmgkb.org) began in 2000 as a repository of pharmacogenetic 
and pharmacogenomic primary data and simple associations between drugs and 
genes found in the literature. PharmGKB was one of the first resources of its 
kind, and it remains a pre-eminent resource in the field. PharmGKB’s mission 
has evolved over the last ten years to reflect the changing field of 
pharmacogenomics. We now focus on pharmacogenomic knowledge 
acquisition and the application of this knowledge to the clinical arena.  
 
Knowledge acquisition entails aggregating and curating pharmacogenomics 
information, primarily in the form of drug-centered pathways, important 
pharmacogene summaries and detailed annotations of the relationships among 
genetic variation, drugs and diseases. Pathways and gene summaries are peer-
reviewed and published routinely in the journal Pharmacogenetics and 
Genomics. Our group has developed custom annotation tools that capture 
complex pharmacogenomic relationships, including statistical measures of 
study significance and study population parameters, in a structured manner. We 
also continue to develop automated and semi-automated methods for knowledge 
curation.  
 
PharmGKB now pursues clinical applications for the pharmacogenomics 
knowledge we curate. Such applications include personal genome annotations 
and practical guidelines for pharmacogenomics in the clinic. We also organize 
research consortia and facilitate the sharing of data across research groups. The 
International Warfarin Pharmacogenetics Consortium (IWPC), the International 
Warfarin Pharmacogenetics Consortium – Genome Wide Association Studies 
(IWPC-GWA) and the International Tamoxifen Pharmacogenomics Consortium 
(ITPC) are examples. PharmGKB is currently developing several other 
consortia, including a knowledge-centric consortium. The Clinical 
Pharmacogenetics Implementation Consortium (CPIC) uses well-defined 
criteria to evaluate the evidence for clinical applications of pharmacogenetics 
and intends to publish corresponding clinical guidelines.  
 
PharmGKB has already used its manually curated database of drug-genetic 
variant associations to annotate the human genome. Over 1600 variant 
annotations from PharmGKB were screened for quality of evidence and an MD 
determined the clinical relevance of the annotations. PharmGKB is now 
working to build an automated pipeline of human genome annotation. 
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OATP1B1, a liver specific transporter facilitates uptake of several drugs in 
clinical use including statins. The identification of frequent naturally 
occurring single nucleotide polymorphisms (SNPs) with effect on transport 
activity was basis of in vivo studies. Various authors could show that 
reduced hepatic uptake translates into significantly higher exposure with 
substrate drugs. In accordance OATP1B1 polymorphisms were identified as 
predictor of statin induced myopathy.  
In order to evaluate the impact of OATP1B1 polymorphisms on 
pharmacodynamics of statins we employed a population-based survey. The 
study of health in Pomerania (SHIP) gathered clinical parameters of 3576 
individuals, a total of 191 individuals with dyslipidemia during the first 
recruitment (SHIP-0) were treated with statins in the 5-year follow-up 
(SHIP-1). In this treatment group individuals harbouring the 521C variant 
exhibited an 11.6% and 12.6% lower reduction of LDL- and total 
cholesterol plasma levels, respectively. Stratification for compounds 
revealed a genotype effect on simvastatin and pravastatin efficacy, while 
atorvastatin appeared to be independent of OATP1B1. A second measure 
for statin efficacy was the likelihood to achieve ASC-target cholesterol 
levels. 377 individuals treated with statins in SHIP-1 were included in this 
analysis. In the case of simvastatin and pravastatin treatment those 
individuals harbouring the 521C allele were less likely to achieve the 
treatment goals. Again, no such genotype effect was detectible in patients 
treated with atorvastatin.  
In conclusion, genetic variants of OATP1B1 are associated with changes in 
statin efficacy in a general population. Importantly the genotype effect 
profoundly varies for individual statins.  
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PHARMACOGENETICS OF DIABETES DRUGS: CANDIDATE GENES 
ENCODING DRUG TRANSPORTERS AND METABOLISM ENZYMES 
 
Kaixin Zhou, Roger Tavendale, Andrew D Morris, Colin N Palmer, Ewan 
Pearson  
 
University of Dundee, Biomedical Research Institute, Dundee, DD1 9SY, 
United Kingdom 
 
Background: 
Considerable variation exists in type 2 diabetes patients' response to common 
Oral Hyperglycaemic Agents (OHA), which include metformin, sulphonylureas 
and thiazolidinediones (TZDs). Pharmacokenetic studies in healthy volunteers 
have established that genetic variants in OHA transporter genes (eg. SLC22A1 
for metformin and SLCO1B1 for TZDs) and metabolism enzyme genes (eg. 
CYP2C8 for TZD and CYP2C9 for sulphonylureas) can affect the disposition of 
these drugs, hence change the exposure levels. Whilst effort is being channelled 
into hypothesis free genome wide association studies of OHA response, 
candidate gene studies of these drug transporters and key metabolism enzymes 
still have considerable merit. We aim to explore whether these genetic variants 
have an impact on OHA response in clinical practice. 
Methods 
Data was obtained from 8000 type 2 diabetes patients in the Go-DARTS cohort. 
As a measure of response we determined failure to achieve a treatment target of 
HbA1C<7%, in around 3000, 2000 and 850 patients for metformin, 
sulphonylureas and TZDs treated patients respectively. We assessed the 
associations between response and genetic variants in CYP2C8, CYP2C9, 
SLC22A1 and SLCO1B1 by logistic regression analysis with adjustment for 
appropriate covariates such as dose, duration, and adherence.  
Results 
Among sulphonylureas treated patients, those homozygote for CYP2C9 *2 or 
*3 alleles were 3.4 times (p=0.0009) more likely to achieve the treatment target 
than wild type carriers. No association was observed between SLC22A1 variant 
420del/R61C and metformin response. Among TZD treated patients, those with 
two copies of the gain of function CYP2C8 *3 or *4 allele were 1.4 times 
(p=0.04) more likely to fail the treatment target whilst those with one or more 
copies of the SLCO1B1 *5 and *15 haplotypes were more likely to achieve the 
treatment target than wild type carriers (p=0.03). This result is of importance 
due to conflicting in vitro and in vivo evidence regarding the role of SLCO1B1 
in the disposition of rosiglitazone and pioglitazone. 
Conclusions 
Using data from this large type 2 diabetes cohort, we have shown that genetic 
variants in OHA transporters and metabolism enzyme genes influence the 
treatment efficacy in clinical practice. The effect sizes observed in this study 
also suggest that even larger samples are required for genome wide association 
studies to overcome the multiple test penalty and unequivocally demonstrate the 
genetic effects in these genes with such strong functional candidacy. 
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ACCURACY OF PHARMACOMETRIC A PRIORI AND A POSTERIORI 
DOSE PREDICTIONS OF WARFARIN  
 
Anna-Karin Hamberg1, Mia Wadelius1, Munir Pirmohamed2, Niclas Jonsson3,4  
 
1Clin Pharmacology, Dep of Medical Sciences, Uppsala, 751 85, Sweden, 
2Wolfson Centre for Personalised Medicine, Dep of Pharmacology, Liverpool, 
L69 3BX, United Kingdom, 3Exprimo NV, Applied Pharmacometrics, 
Mechelen, B-2800 , Belgium, 4Div of Pharmacokinetics and Drug Therapy, Dep 
of Pharmaceutical Biosciences, Uppsala, 751 24, Sweden 
 
Objective: To evaluate the accuracy of a pharmacometric a priori and a 
posteriori warfarin dose prediction model [1].  
Background: Warfarin therapy is challenging due to its narrow therapeutic 
range and pronounced variability in individual dose response. We have 
developed a NONMEM model for the relationship between warfarin dose and 
INR response, which includes CYP2C9 and VKORC1 genotype, and age [1]. 
Six published dosing algorithms for a priori dose predictions were recently 
compared [2], and the IWPC [3] and Gage [4] algorithms were found most 
accurate.  
Method: Warfarin patients enrolled in a prospective UK study [5,6] and who 
met all of the following criteria were included in the evaluation dataset: a target 
INR of 2.0-3.0, achieved a stable, therapeutic warfarin dose (three consecutive 
INRs within target at same daily dose), information on CYP2C9 and VKORC1 
genotype, sex, age, weight, height and concomitant treatment with amiodarone 
or enzyme inducers. The IWPC and Gage algorithms [3,4] and a 5 mg fixed 
dose were included in our evaluation of a priori dose predictions. The dose 
revision algorithm by Lenzini [7] was included in the evaluation of a posteriori 
dose predictions. Predictive accuracy was based on the difference between 
predicted and actual dose, including calculation of mean absolute error, extent 
of predicted doses within an acceptable range, and extent of severe over-
prediction [2].  
Results: Our model can be used to predict warfarin dose during all phases of 
treatment, irrespective of target INR. Preliminary results suggest that it gave 
slightly less accurate a priori dose predictions than the two published 
algorithms [3,4]. The evaluation of a posteriori dose predictions is ongoing.  
Acknowledgements: A. Jorgensen and S. Lane at The University of Liverpool 
and S. Bourgeois at Sanger Institute for facilitating access to the British data. 
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CLINICAL UTILITY OF TOMM40 RS10524523 FOR THE 
PREDICTION OF ALZHEIMER’S DISEASE 
 
Allen D Roses1, Michael W Lutz1, Donna G Crenshaw1, Ann M Saunders1, 
Sterling C Johnson2, Mark A Sager2, Richard J Caselli3  
 
1Duke University, Deane Drug Discovery Institute, Durham, NC, 27708, 2UW 
Medical School-Madison, Department of Medicine, Madison, WI, 53705, 
3Mayo Clinic Arizona, Department of Neurology, Scottsdale, AZ, 85259 
 
A phylogenetic analysis of sequence data from the linkage region containing 
TOMM40 and APOE identified an association between genotype at a 
polymorphic poly-T tract, rs10524523 (523), in TOMM40 with age at onset 
distributions of Alzheimer’s disease (AD). This study also revealed the unique 
linkages between 523 and APOE alleles: APOE4 is linked to a long (L) 523 
allele whereas APOE3 is linked to a short (S) or a very long (VL) poly-T in two, 
evolutionarily distinct haplotypes. Longer poly-T tracts (L and VL) are 
associated with earlier age of AD onset. This association is now confirmed in a 
prospective study of aging (Mayo Clinic, Scottsdale).  
 
Poly-T length is also associated with memory, learning and brain grey matter 
volume in cognitively normal, adult children of AD patients (Wisconsin 
Alzheimer’s Institute). APOE3/3, 523 VL homozygotes perform significantly 
worse on the Rey Auditory Verbal Learning Test of memory and learning than 
S/S homozygotes. APOE3/3 VL/VL subjects also have reduced grey matter 
volume in the ventral posterior cingulate and precuneus, regions known to be 
affected early in AD, relative to APOE3/3 subjects who carry two short 523 
alleles. These results indicate that genotype at the poly-T locus identifies 
individuals who, although cognitively normal, express important biomarkers of 
incipient disease. The associations between 523 genotype and other dynamic 
biomarkers are being studied in this normal cohort to frame recently published 
hypothetical data regarding the timing of appearance of these biomarkers.  
 
In contrast to 523, SNPs that have been identified by GWAS of AD, with the 
exception of SNPs in the APOE-TOMM40 linkage region, have low predictive 
utility for disease risk or age of onset, have a more tenuous connection to 
known disease biology, and are unrelated to expression of known disease 
biomarkers. Without a biological context or a compelling statistical case for 
disease prediction, these GWAS findings are distant from translation into drug 
discovery and development or clinical practice.  
 
The performance of 523-genotype as a diagnostic will be tested as one objective 
of a pharmacogenetically assisted delay of AD onset clinical trial, OPAL. For 
OPAL, cognitively normal individuals, judged to be at high disease risk based 
on 523 and APOE genotypes and age, will be randomized to receive drug or 
placebo. Low risk subjects will receive placebo, but the inclusion of this group 
provides data for assessment of the clinical performance characteristics of the 
genetic test of disease risk.  
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VISITOR INFORMATION 
 
EMERGENCY                CSHL                          BANBURY 
Fire (9) 742-3300 (9) 692-4747 
Ambulance (9) 742-3300 (9) 692-4747 
Poison (9) 542-2323 (9) 542-2323 
Police (9) 911 (9) 549-8800 
Safety-Security Extension 8870  
 
Emergency Room 
Huntington Hospital 
270 Park Avenue, Huntington 
631-351-2300 
(1037)  
Dentists 
Dr. William Berg 
Dr. Robert Zeman 
 
631-271-2310 
631-271-8090 
Doctor 
MediCenter 
234 W. Jericho Tpke., Huntington Station 
631-423-5400 
(1034) 
Drugs - 24 hours, 7 days 
Rite-Aid 
391 W. Main Street, Huntington 
631-549-9400 
(1039) 
Free Speed Dial 
Dial the four numbers (****) from any tan house phone to place a 
free call. 
GENERAL INFORMATION 
 
Books, Gifts, Snacks, Clothing, Newspapers 
 BOOKSTORE   367-8837 (hours posted on door) 
 Located in Grace Auditorium, lower level. 
 
Photocopiers, Journals, Periodicals, Books, Newspapers 
 Photocopying – Main Library 
 Hours:  8:00 a.m. – 9:00 p.m. Mon-Fri 
             10:00 a.m. – 6:00 p.m. Saturday 
Helpful tips - Obtain PIN from Meetings & Courses Office  
to enter Library after hours.  See Library staff for photocopier 
code. 
 
Computers, E-mail, Internet access 
 Grace Auditorium 
 Upper level: E-mail only 
 Lower level: Word processing and printing. 
 STMP server address: mail.optonline.net 
 To access your E-mail, you must know the name of your  
 home server.    
 
Dining, Bar 
 Blackford Hall 
  Breakfast  7:30–9:00, Lunch 11:30–1:30, Dinner  5:30–7:00 
  Bar  5:00 p.m. until late  
 Helpful tip - If there is a line at the upper dining area, try the  
 lower dining room 
 
 
 
Messages, Mail, Faxes 
 Message Board, Grace, lower level 
 
Swimming, Tennis, Jogging, Hiking 
June–Sept. Lifeguard on duty at the beach. 12:00 noon–6:00 p.m.  
Two tennis courts open daily. 
 
Russell Fitness Center 
 Dolan Hall, east wing, lower level 
 PIN#:  Press 64565 (then enter #) 
 
Concierge 
 On duty daily at Meetings & Courses Office. 
After hours – From tan house phones, dial x8870 for 
assistance 
  
Pay Phones, House Phones 
Grace, lower level; Cabin Complex; Blackford Hall; Dolan Hall, 
foyer  
 
CSHL’s Green Campus 
 
Cold Spring Harbor Laboratory is pledged to operate in an 
environmentally responsible fashion wherever possible.  In the past, 
we have removed underground oil tanks, remediated asbestos in 
historic buildings, and taken substantial measures to ensure the 
pristine quality of the waters of the harbor. Water used for irrigation 
comes from natural springs and wells on the property itself.  Lawns, 
trees, and planting beds are managed organically whenever possible.  
And trees are planted to replace those felled for construction 
projects.   
 
Two areas in which the Laboratory has focused recent efforts have 
been those of waste management and energy conservation.  The 
Laboratory currently recycles most waste.  Scrap metal, electronics, 
construction debris, batteries, fluorescent light bulbs, toner cartridges, 
and waste oil are all recycled.  For general waste, the Laboratory uses 
a “single stream waste management” system, removing recyclable 
materials and sending the remaining combustible trash to a 
cogeneration plant where it is burned to provide electricity, an 
approach considered among the most energy efficient, while providing 
a high yield of recyclable materials. 
 
Equal attention has been paid to energy conservation.  Most lighting 
fixtures have been replaced with high efficiency fluorescent fixtures, 
and thousands of incandescent bulbs throughout campus have been 
replaced with compact fluorescents.  The Laboratory has also 
embarked on a project that will replace all building management 
systems on campus, reducing heating and cooling costs by as much 
as twenty-five per cent. 
 
Cold Spring Harbor Laboratory continues to explore new ways in 
which we can reduce our environmental footprint, including 
encouraging our visitors and employees to use reusable containers, 
conserve energy, and suggest areas in which the Laboratory’s efforts 
can be improved. This book, for example, is printed on recycled 
paper. 
                       1-800 Access Numbers 
 
 AT&T  9-1-800-321-0288 
 MCI  9-1-800-674-7000 
 
Local Interest 
 Fish Hatchery   631-692-6768 
 Sagamore Hill   516-922-4447 
 Whaling Museum   631-367-3418 
 Heckscher Museum  631-351-3250 
 CSHL DNA Learning  x 5170 
   Center 
 
New York City 
 Helpful tip - 
 Take Syosset Taxi to Syosset Train Station 
 ($8.00 per person, 15 minute ride), then catch Long Island  
 Railroad to Penn Station (33rd Street & 7th Avenue).   
 Train ride about one hour. 
 
   TRANSPORTATION 
Limo, Taxi 
 Syosset Limousine  516-364-9681  (1031) 
 Super Shuttle  800-957-4533  (1033) 
  To head west of CSHL - Syosset train station 
  Syosset Taxi  516-921-2141  (1030) 
 To head east of CSHL - Huntington Village  
  Orange & White Taxi 631-271-3600  (1032) 
Executive Limo  631-696-8000  (1047) 
 
Trains 
 Long Island Rail Road   822-LIRR  
 Schedules available from the Meetings & Courses Office. 
 Amtrak   800-872-7245 
 MetroNorth   800-638-7646 
 New Jersey Transit  201-762-5100 
 
Ferries 
 Bridgeport / Port Jefferson 631-473-0286 (1036) 
 Orient Point/ New London 631-323-2525 (1038) 
 
Car Rentals 
 Avis   631-271-9300 
 Enterprise   631-424-8300 
 Hertz   631-427-6106 
  
Airlines 
 American   800-433-7300 
 America West  800-237-9292 
 British Airways  800-247-9297 
 Continental   800-525-0280 
 Delta   800-221-1212 
 Japan Airlines  800-525-3663 
 Jet Blue   800-538-2583 
 KLM   800-374-7747 
 Lufthansa   800-645-3880 
 Northwest   800-225-2525 
 United   800-241-6522 
 US Airways   800-428-4322 
